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Peripheral Artery Disease (PAD) affects over 200 million people worldwide 
with a 5-year mortality rate as high as 30%. Atherosclerotic blockages impair blood 
flow to the lower limbs, causing ischemic leg pain and dysfunction upon exercise 
that later progresses to ulcerations and gangrene and often requires amputation. 
The standard therapies, revascularization and exercise, allow patients to walk 
further and longer but are at best maintained short-term. One explanation may be 
the development of myopathic changes in the limb that progress despite improved 
hemodynamics—a paradigm shift in the classic view of PAD pathophysiology as 
solely a mismatch between blood supply and demand. Thus, it is imperative that 
we characterize aspects of this myopathy, identify their functional consequences, 
and determine how their development is affected by standard therapies. Such 
knowledge is critical to developing adjunct therapeutic strategies that directly target 
the myopathy to improve the limb function of PAD patients. Excessive extracellular 
matrix deposition, or fibrosis, causes end-organ dysfunction in cardiovascular 
diseases. In the gastrocnemius of PAD patients, we have localized increased 
11 
 
expression of a key pro-fibrotic cytokine Transforming Growth Factor-Beta 1 (TGF-
β1) to microvessels and demonstrated a direct relationship with collagen 
deposition through advancing disease stages of PAD. We determined that 
vascular smooth muscle cells and not macrophages, T cells, fibroblasts, or 
endothelia, are the primary producers. We also demonstrated an inverse 
relationship between vascular TGF-β1 expression and hemodynamics, which 
suggests that local ischemia-hypoxia may induce TGF-β1 expression. Our study 
of PAD patients with unilateral disease confirmed that TGF-β1 dependent 
myofibrosis is a localized response in the ischemic muscle without significant 
systemic contributions. Collectively, the data suggest that the development of 
myofibrosis in PAD is of a vascular etiology. To determine how myofibrosis is 
affected by standard therapies, patients either underwent revascularization, 
supervised exercise therapy, or received no interventions for 6 months. Biopsies 
and limb function measurements were obtained at baseline and 6 months. Without 
intervention, myofibrosis progressed in the gastrocnemius of PAD patients but did 
not alter limb function. Patients in the exercise group had increased myofibrosis 
despite improved limb function. However, myofibrosis did not progress in patients 
who underwent revascularization. These data suggest that long term benefits to 
the lower limb of PAD patients are better with revascularization than exercise by 
preventing myofibrosis progression. Moreover, benefits of exercise on limb 
function are not due to alterations in myofibrosis. Overall, the findings validate the 
need for adjunct therapies that directly decrease TGF-β1 expression, given that 
neither revascularization nor exercise reverses myofibrosis in PAD patients. 
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CHAPTER I: INTRODUCTION & BACKGROUND  
Atherosclerosis and Peripheral Artery Disease 
 Atherosclerosis is one of the leading causes of morbidity and mortality 
worldwide with important implications for public health and primary care1. This 
systemic disease affects the large and medium sized arteries and causes luminal 
narrowing due to the formation of plaques. These plaques are the accumulation of 
lipid and fibrous material between the intimal and medial layers of the vessels1. 
Peripheral artery disease (PAD) is the non-cardiac manifestation of 
atherosclerosis, where plaques are most commonly found in the aortoiliac and 
femoropopliteal regions of vasculature supplying the lower extremities2. 
Development of these plaques increasingly impair blood flow to the lower limbs, 
creating a supply and demand mismatch when patients exercise.  
The development of PAD symptoms has been classified into four distinct 
disease stages3. PAD patients who are asymptomatic are at Fontaine Stage I. 
When patients experience the first symptoms of claudication, or ischemic leg pain 
and gait dysfunction upon exercise that is relieved by rest, they have progressed 
to Fontaine Stage II. At Fontaine Stage III, claudication occurs even at rest. When 
ischemia becomes critical at Fontaine Stage IV ulcerations and necrosis develop 
in the limbs and may require amputation. Transition between these stages often 
takes decades and as a result, PAD patients live with chronic debilitating pain, are 
unable to walk normally, and have poor quality of life4.  
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The epidemiology of PAD in recent years has become alarming, both 
globally and in the United States, and is attributable to increased exposure to risk 
factors. In the past 20 years, there has been a worldwide increase in PAD-related 
death and disability5,6. PAD now affects over 200 million people worldwide and 
approximately 12 million in the United States alone. In addition to genetics and 
ethnicity, advancing age alone is a major underlying risk factor, where the 
prevalence of PAD increases from 1% to approximately 15% from age 40 to 707. 
Avoidable risk factors are those related to lifestyle choices, which include tobacco, 
unhealthy diets, obesity, and lack of physical activity, and the management of co-
morbid conditions. Given the causal linkage between tobacco and atherosclerosis, 
smokers have a greater relative risk for developing PAD (2.71), which is even 
higher than for coronary artery disease (1.67)8. Those who have hypertension or 
diabetes are at significantly greater risks of developing PAD due to the damaging 
effects of these conditions on vascular integrity and function. Hyperlipidemia is a 
constellation of abnormalities that include high cholesterol, triglycerides, and 
lipoproteins, all of which promote atherosclerosis and increases the risk of 
developing PAD. Finally, elevated levels of pro-thrombotic factors, inflammatory 
markers, and homocysteine in circulation are also known risk factors, which 
reflects the systemic nature of atherosclerosis, where the pathological factors from 
one plaque site can stimulate formation at other sites and affect the development 
and natural history of PAD in patients.  The relative odds ratios for these risk 
factors for PAD is presented in Figure 1.1.  
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Figure 1.1: The Relative Contributions of Risk Factors to Development of 
Peripheral Artery Disease. Modified from: Intersociety Consensus for the 
Management of Peripheral Arterial Disease (TASC II)9.  
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PAD patients are at increased risk of morbidity and mortality. The inability 
of PAD patients to walk normally due to claudication is, in itself, a risk factor for 
other co-morbid conditions. Since the majority of PAD patients are elderly and 
walking is the primary physical activity of the elderly, claudicating patients adopt a 
sedentary lifestyle that further escalates their risk for adverse health events. PAD 
patients have an increased risk for myocardial infarction, and renal and 
cerebrovascular disease and diabetes9-11. The consequence of this is highlighted 
by mortality studies. Those diagnosed with PAD have an average life expectancy 
of just 16 years that is reduced by almost 90% to 1.5 years either with a subsequent 
stroke or myocardial infarction, and this drastic drop is comparable to coronary 
artery disease and worse than cerebrovascular disease (Table 1.1). Moreover, 5-
year mortality rates for those diagnosed with PAD are as high as 30%12.  
 
Subsequent Adverse Event Diagnosed Condition or Adverse Event 
 PAD AMI Stroke 
None 16.0 13.9 8.80 
AMI 1.60 0.40 4.20 
Stroke 1.50 0.40 3.30 
 
 
Table 1.1: The Life Expectancy, in Years, of PAD Patients with Subsequent 
Co-Morbid Adverse Events Relative to Other Cardiovascular Diseases. 
Modified from the Framingham Study13. 
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Given the epidemiology of PAD, this disease presents a significant financial 
burden on health care systems. PAD patients have recurring hospitalizations and 
outpatient care that incur substantial costs due to the chronicity of its natural 
history14,15. It is estimated that approximately $4 billion are paid by Medicare each 
year for PAD-related care that rivals congestive heart failure and cerebrovascular 
disease (4 billion each), and greater than cardiac dysrhythmias (2.7 billion). PAD 
patients are also costlier than the typical elderly Medicare beneficiary, with mean 
expenditures of about $14,000 compared to the average of $5800. The majority of 
these costs are incurred by inpatient care to treat severe manifestations of limb 
ischemia14,15. Thus, outpatient preventative care and alternative treatment 
strategies can drive down costs. Overall, PAD is a major health problem with high 
morbidity and mortality, and is very costly to the health care system.   
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The Pathophysiology of Limb Dysfunction in Peripheral Artery Disease  
The pathophysiology of limb dysfunction in PAD is complex, being more 
than simply a mismatch between blood supply and demand16,17. A widely held view 
is that limb dysfunction is exclusively produced by claudication, during which 
metabolic demands rapidly increase but the blood flow required cannot be 
delivered due to the atherosclerotic blockages, causing the limb to become 
progressively more ischemic, painful and impaired. However, we now know that 
hemodynamic changes are not the sole contributor. Advanced biomechanical gait 
analysis of claudicating patients has shown that gait dysfunction is present even 
before onset of claudication. This suggests that a myopathy may be present that 
causes limb dysfunction in PAD patients.  
A series of biomechanical studies have analyzed the kinetics and 
kinematics of the legs of claudicating patients. Lower extremity kinetics are an 
evaluation of the forces exerted by the weight bearing limbs of PAD patients on 
the ground18. These ground reaction forces are a direct application of Newton’s 
third law of motion, in which the ambulating PAD patient pushes on the ground 
with a force and the ground exerts an equal and opposite force. This force can be 
measured with standard force plates as resolved into three components: vertical, 
anterior-posterior, and medial-lateral. Lower extremity kinematics, on the other 
hand, focuses on the angular displacement of the joints in the leg, measured by 
joint angles, moments, torques and powers18. Kinetic analyses of PAD patients 
demonstrate a significant flattening of the vertical force causing a lower and less 
fluctuant center of mass when ambulating19,20. PAD patients demonstrate 
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decreased propulsion forces in the anterior-posterior direction and increased 
forces in the medial-lateral direction that are consistent with a gait characterized 
by wider steps and an inability to swing their legs straight through19,20. Kinematic 
analyses of PAD patients have measured angles, torques and powers at the hip, 
knee, and ankle joints. PAD patients exhibit greater joint angles which manifests 
in gait as a “foot drop” upon heel touchdown21-23. Torque and power analysis 
demonstrate that PAD patients have decreased abilities of the knee and hip 
extensors and ankle plantar flexors, leading to difficulties in the control weight 
acceptance, support of the trunk, and forward propulsion while walking21-23. 
The defects in gait exhibited by PAD patients have been measured both 
before and after the onset of claudication and show that claudication is not the only 
factor contributing to limb dysfunction. Both kinetic and kinematic abnormalities 
were present before the onset of claudication, usually within the first 3-4 steps 
taken by patients23. The gait dysfunction is also present after onset of claudication 
and worsens. Presence of these alterations both before and after onset suggests 
that limitation of blood flow is not the sole cause and suggests that defects in the 
skeletal muscle of the limbs may also contribute. Additional hemodynamic and 
functional studies of the lower limb of PAD patients support the presence of 
myopathy. During the first few steps taken by PAD patients, tissue oxygenation24 
and blood flow25,26 to the leg are very similar to that of age matched control 
patients. In light of the biomechanical studies, decreased blood flow and tissue 
oxygen levels are not the only mechanisms responsible for the gait dysfunction 
observed in PAD patients before the onset of claudication. This is further 
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corroborated by a study that measured muscle strength in PAD patients using a 5-
second maximal isometric strength assessment that is independent of blood flow27, 
given the short time frame and that isometric contractions produce no discernable 
joint motion. Muscle strength of PAD patients are significantly lower than that of 
age-matched control patients27, again indicating that blood flow is not the only 
determinant of the dysfunction of claudicating muscle.  
Lower limb myopathic changes in PAD patients may be initially caused by 
atherosclerotic blockages that produce chronic cycles of ischemia-reperfusion, 
which occur when patients walk and then have to rest due to claudication. 
Ischemia-reperfusion, and the resulting hypoxia-normoxia, is known to be highly 
damaging to end organs throughout the body28. Pathological mechanisms such as 
oxidative stress and mitochondrial dysfunction are initiated with the flux of stagnant 
blood filled with toxic metabolites that are harmful to the end-organ. In PAD, the 
ischemia-reperfusion injury to skeletal muscle may produce progressive decline in 
the integrity and function of myofibers, ultimately causing their degeneration and 
the inability of patients to walk normally. At some point in this progression, further 
decline in the hemodynamic state of the leg only further aggravates this myopathy. 
This is supported by the inability of interventions that restore blood flow to the legs 
of PAD patients to reverse functional impairment to the degree of improved blood 
flow29. Additionally, functional decline in PAD patients occurs to a greater degree 
than the progression of atherosclerosis in arteries supplying the lower 
extremities30. Thus, it is apparent that preventing future ischemia-reperfusion 
insults does not ameliorate the myopathic changes that have developed and likely 
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continue to progress largely independently of blood flow. This line of reasoning is 
supported by research on interventions against atherosclerosis in other vascular 
beds. Percutaneous revascularization for patients with coronary artery disease 
improves blood flow to the heart, chest pain, and quality of life, but does not 
increase survival rates or reduce the incidence of myocardial infarctions31,32. 
Similarly, percutaneous revascularization of atherosclerosis in renal arteries only 
confers clinical improvements in less than half of the patients, where it was 
postulated that concomitant presence of renal parenchymal disease was 
responsible33. Taken together, this body of research demonstrates that the 
pathophysiology of PAD limb dysfunction has evolved from a purely hemodynamic 
cause to one that is inclusive of myopathy in the lower limb of patients (Figure 
1.2). Such an evolution will provide greater insight into new therapeutic strategies 
to improve limb function of PAD patients. 
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Figure 1.2: The Pathophysiology and Functional Implications of Leg 
Ischemia in Peripheral Artery Disease. Adapted from a Review Paper by Mary 
McDermott34. 
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The Myopathy of Peripheral Artery Disease Decreases Limb Function 
Skeletal muscle is a fascinating biological tissue that is able to transform 
chemical energy to mechanical work, allowing us to function as human beings. The 
functional unit that produces motion at a joint is comprised of the muscle belly and 
tendons that bind muscle to the bone. Within the muscle belly consists of an 
arrangement of muscle cells that produce contraction. The muscle as a whole is 
comprised of multiple fascicles that in turn are made up of myofibers, which are 
long cylindrical multinucleated cells filled with smaller units of filaments organized 
in parallel to the orientation of the myofiber. The largest filamentous structure is 
the myofibril that is composed of sarcomere subunits arranged end-to-end along 
the length of the myofibril. Within the sarcomere are myofilaments that contain 
actin and myosin proteins responsible for the sliding mechanism of muscle 
contraction, utilizing large amounts of oxygen in the process. When PAD patients 
exercise the demand for oxygen to fuel these muscular contractions increases and 
is not met by the restricted blood flow. As a result, specific muscle groups in the 
lower limbs of PAD patients do not perform optimally, producing biomechanical 
defects and limb dysfunction. The myopathy of PAD patients has been best 
characterized in the gastrocnemius muscle16.  
The gastrocnemius is the largest and most powerful muscle in the calf 
responsible for running, jumping, and walking, and the integrity and function of this 
muscle is compromised in PAD patients. Histomorphological changes observed by 
light microscopic evaluation include necrosis, phagocytosis, and presence of 
central nuclei in myofibers, all of which correlate with severity of occlusion35,36. 
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Electron microscopy revealed ultrastructural changes in sarcomere that were 
highly disorganized and often disintegrated37,38. A more recent study found 
desmin, an intermediate filament of the myofibril, to abnormally accumulate in the 
gastrocnemius of PAD patients in a honeycombed and/or amorphous aggregate 
rather than its normal registration with Z-disks of sarcomeres39. The main function 
of desmin is to transmit forces produced by myofibrils by linking them into bundles 
and connecting them to specialized site of adhesions in the sarcolemma40. Thus, 
alterations in desmin will not allow myofibrillar forces to be transferred to the 
extracellular matrix and ultimately to the tendons for normal movement of the limb. 
Desmin also provides organizational support for the mitochondrial system and may 
contribute to mechano-chemical signaling between various compartments of the 
myofiber41. It is well established that cytoskeletal abnormalities are associated with 
muscle pathologies and decreased function of the sarcomere42. In PAD patients, 
desmin abnormalities strongly correlated with altered myofiber morphology, 
reduced mitochondrial respiration, and impaired walking ability in PAD patients39.  
The gradual degradation of gastrocnemius histology in PAD has been 
quantified non-invasively via imaging, but more recently, morphometric 
quantitative methods have allowed measurements of this progression within 
muscle biopsies in relation to limb function. Histologically, myofiber degeneration 
is not only characterized by decreased size, but also variation in shape, both of 
which become more abnormal with increasing PAD disease severity. Classically, 
myofiber cross-sectional area has been measured by computed tomography43. 
However, with imaging techniques, subtler changes in the shape of the myofibers 
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without significant change in size, is difficult to measure and may be early changes 
predictive of PAD development. Recently, morphometric analytical methods 
employing immunofluorescence staining of the sarcolemma of gastrocnemius 
biopsies from PAD patients, have allowed extraction of the myofibers into a binary 
mask, upon which changes in the size and shape of the myofiber can be measured 
with software algorithms. The morphological changes that were found to be 
progressively abnormal in the skeletal muscle include myofiber cross-sectional 
area, density, roundness, and distance of the major and minor axes. Using the 
combination of these parameters, discrimination of PAD patients at different 
Fontaine stages and from age-matched controls was achieved with an 88% 
accuracy44. Furthermore, these abnormalities in myofiber morphometrics are 
closely linked to the muscle strength and limb function of PAD patients45. The 
ability to measure myofiber morphology on a muscle biopsy also permits direct 
correlations with other aspects of myopathy, such as mitochondrial dysfunction 
and oxidative damage, in the same muscle biopsy.  
The gastrocnemius of PAD patients, as well as other calf muscles, 
experience cycles of ischemia-reperfusion injury that produces oxidative stress 
and mitochondrial dysfunction28,46. During ischemia, the interruption of blood 
supply reduces oxygen and nutrient delivery to the myofibers. Generation of ATP 
by oxidative phosphorylation is disrupted to impair metabolism and energy 
dependent cellular functions47. In the lower limb of PAD patients, mitochondria 
demonstrate inefficient utilization of Kreb cycles components, impaired oxygen 
use, and have decreased amounts of electron transport chain components that 
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correlate with the extent of functional impairment48,49. Phosphorus-31 nuclear 
magnetic resonance spectroscopy studies of PAD claudicants suggested 
respiratory defects in mitochondrial bioenergetics50, which was confirmed by 
studies that found Complexes I, III, and IV of the electron transport chain to be 
dysfunctional51,52. All of these changes in the mitochondria contribute to electrons 
being backed up where they may leak out and interact with the high influx of 
molecular oxygen that occurs with reperfusion to form reactive oxygen species 
(ROS)53. Reperfusion also introduces accumulations of circulating cells such as 
leukocytes, which have become activated to produce ROS via NADPH-oxidase. 
During ischemia, activation of cell survival programs and immune responses that 
promote angiogenesis, remodeling, and repair upregulate expression of adhesion 
molecules that aide transmigration and activation of leukocytes. The subsequent 
release of ROS from these leukocytes have cytotoxic effects on myocytes.  
Additional ROS contributions in PAD skeletal muscle comes from increased 
activity of xanthine oxidase. During ischemia, inefficient mitochondrial respiration 
produces buildup of ADP that is metabolized into hypoxanthine and xanthine, both 
of which are substrates for xanthine oxidase28,46. When reperfusion occurs, 
xanthine oxidase is provided with ample molecular oxygen, the other substrate 
needed along with hypoxanthine or xanthine to produce superoxide anion28,46. 
Moreover, manganese superoxide dismutase, a major antioxidant enzyme is 
reported to be deficient in PAD gastrocnemius51, which further permits the 
accumulation of ROS. Excessive ROS is known to induce damage of DNA and 
proteins in virtually all biomolecular in cells and tissues. In PAD, mitochondrial DNA 
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and protein may be targets of oxidative stress, which further exacerbates the 
myopathy and accelerates limb dysfunction in patients. 
Further support for mitochondrial injury and oxidative damage can be found 
in histomorphological studies of PAD calf muscle. Electron microscopy has 
revealed mitochondria to be both qualitatively and quantitatively abnormal, 
demonstrating hypertrophy, hyperplasia, hypercristae, transverse orientation, 
paracrystalline inclusions, and lipid vacuolizations37,38 all of which support the 
mitochondria being leaky to electrons that help form free radicals. The damage 
caused by ROS generated from the mitochondria is reflected by presence of 
oxidatively damage proteins, marked by carbonyl adducts, and lipids, reflected by 
the 4-hydroxynonenal content. Compared to age-matched controls, PAD 
claudicants had significantly higher carbonyl and 4-HNE in the myofibers, which 
was associated with fewer myofibers and more advanced Fontaine stages of 
disease54. Thus, ischemia-reperfusion via mitochondrial dysfunction and oxidative 
stress induce the degeneration of myofibers and limb dysfunction.  
Myopathy caused by ischemia-reperfusion likely extends to encompass the 
reparative phase of ischemia-reperfusion injury. During ischemia, low 
concentrations of ROS can signal survival programs by increasing growth factors 
that promote angiogenesis, induce proliferation and differentiation of vascular 
smooth muscle cells for vascular remodeling, and activate inflammatory and pro-
fibrotic cytokines that contribute to tissue remodeling and formation of scar 
tissue28,46. However, when ischemia-reperfusion is not relieved and is allowed to 
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develop over decades as in PAD patients, many of these beneficial adaptations 
are chronically activated, which actually produces pathological responses. Such 
findings have been reported in coronary and cerebrovascular manifestations of 
atherosclerosis and is likely a part of the myopathy of PAD55. Given the systemic 
nature of atherosclerosis, inflammatory factors in circulation have been thought to 
further induce disease56. In the serum of PAD patients, inflammatory factors such 
as C-reactive protein can help more accurately screen PAD patients57, and predict 
disease severity58, functional decline59, and mortality60. Thus, they may influence 
the development and progression of PAD myopathy, such as by activating 
leukocytes that infiltrate into the muscle and release cytotoxic ROS. It has been 
shown in the heart and brain that as more cells dies, damage associated molecular 
patterns accumulate and chronically stimulate toll like receptors to activate innate 
immune responses that are associated with increased ROS, cell death, and 
fibrosis61. In PAD, it was recently shown that toll like receptors are upregulated in 
the muscle biopsies of PAD compared to age-matched control patients62. 
In addition to systemic inflammatory responses, cytokine profiling of the 
gastrocnemius of PAD claudicants is suggestive of local aberrant immune and 
fibrotic responses. Comparisons of the cytokines in serum and gastrocnemius 
show they are very different. First, the majority of pro-inflammatory (TNF-α, IFN-γ, 
IL-6, IL-8, and IL-12) and anti-inflammatory (IL-2, IL-10, and IL-13) cytokines were 
present in the gastrocnemius of PAD patients more often than in the serum, and 
also at much higher levels (Table 1.2). The exceptions were the pro-inflammatory 
chemokine CCL5, which is known to recruit monocytes, and anti-inflammatory 
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cytokine Transforming Growth Factor-Beta 1 (TGF-β1) which was present in 
robust quantities both the muscle and serum. Yet, the levels in the serum are lower 
than muscle, indicating that the local cytokine milieu that drives myopathy cannot 
be accounted for by levels in the circulation. This is supported by a study of 17 
PAD patients with unilateral disease that found the total neutrophil number and 
percent activated were higher in venous blood draining from the diseased limb 
than in arterial blood, differences that were not exhibited in the contralateral limb63. 
Another study of PAD patients with unilateral disease also demonstrate a venous-
arterial difference of neutrophil myeloperoxidase, which is an index of neutrophil 
activation64,65. Myeloperoxidase uses nitric oxide which reduces its bioavailability 
to endothelia for proper vasodilatory functions and modulation of adhesion 
molecules, rendering endothelia dysfunctional66. Overall, such aberrant immune 
responses may adversely affect the microcirculation and skeletal muscle repair, 
which further compromises limb function.  
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Table 1.2. Cytokine Profile in Gastrocnemius and Serum of PAD Claudicants. 
Unpublished laboratory data that is currently in preparation for manuscript 
submission. ND = Not Detected. N/A = Not Applicable. 
  
This theory is highlighted by the findings of robust and consistent increases 
in CCL5 and TGF-β1 in PAD patients, both of which may contribute to myofibrosis. 
Compared to age-matched controls, CCL5 and TGF-β1 were at least 3-fold greater 
in the gastrocnemius of PAD compared to age-matched control patients (Table 
1.3). The role of CCL5 is to recruit monocytes, which are essential for the 
reparative phase of ischemia-reperfusion injury67. The role of TGF-β1 is multi-
faceted, being released by immune cells to resolve inflammation but also induce 
wound healing68. The abnormally high levels of these two cytokines suggests a 
pathological fibrotic response and is consistent with maladaptations associated 
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with chronic activation of the reparative phase of ischemia-reperfusion injury in 
coronary artery and cerebrovascular disease28,46. Both indirect and direct evidence 
exists for pathological fibrosis in the gastrocnemius of PAD patients. Computed 
tomography of the lower limb of PAD patients and age-matched controls show 
increasing hypodense areas in between myofascicles that could be accumulation 
of extracellular matrix, and this is much more evident on hematoxylin and eosin 
histology (Figure 1.3). However, the relationship between TGF-β1 and fibrosis in 
the lower limb skeletal muscle of PAD patients has never been examined. This 
unexplored aspect of PAD myopathy may have substantial functional 
consequences.  
 
Table 1.3. Cytokine Profile of PAD and Control Patient Gastrocnemius. 
Unpublished laboratory data that is currently in preparation for manuscript 
submission. ND = Not Detected. N/A = Not Applicable. 
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Figure 1.3. Computed Tomography and Hematoxylin and Eosin Stain of PAD 
and Control Patient Gastrocnemius Demonstrating Increased Extracellular 
Matrix. Unpublished laboratory data that is currently in preparation. 
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Roles of TGF-β1 in Skeletal Muscle Repair and Pathological Fibrosis 
Fibrosis is a common pathobiological outcome of many chronic diseases, 
which includes the myopathy of PAD. In pulmonary fibrosis, liver cirrhosis, and 
cardiac remodeling, excessive deposition of extracellular matrix over time leads to 
loss of both tissue architecture and organ function. Despite their end organ 
diversity, all fibrotic processes are thought to arise from abnormalities of wound 
healing and regenerative responses69. In skeletal muscle, this occurs via an 
orchestrated response to sterile injury. Vascular and infiltrating immune cells 
release cytokines and growth factors that mediate survival and proliferation of 
living myocytes, while clearing remnants of dead ones70,71. Next, activation of 
satellite cells with stem cell capacity initiates formation of new myocytes to replace 
lost or damaged myofibers. Efficient repair also requires migration and proliferation 
of activated myofibroblasts that produce temporary extracellular matrix 
components, such as collagen, to stabilize healing tissue. Throughout the repair 
process, specific proteases and their inhibitors are activated to remove this 
temporary extracellular matrix, such that fibrotic components do not interfere with 
myofiber function once regeneration is complete. Fibrosis is thought to be the 
consequence of abnormal persistence of these coordinated processes, leading to 
excessive and irreversible extracellular matrix deposition69. Currently, pro-fibrotic 
cytokine interactions are active areas of research aimed at preventing and/or 
slowing progression of end-organ dysfunction.  
TGF-β1 is potent pro-fibrotic cytokine elevated in numerous fibrotic 
diseases, where it induces myofibroblast activation71. In response to TGF-β1, 
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fibroblasts transform into myofibroblasts, which synthesize and release 
extracellular matrix and protease inhibitors that prevent enzymatic degradation of 
extracellular matrix72-75. The major mechanism by which TGF-β1 promotes fibrosis 
is signaling through the Smad family of transcription factors, which transactivate 
genes for collagen and inhibitors of collagenases68. Myofibroblasts are further 
characterized by increases in alpha-smooth muscle actin, cell proliferation, and 
migration during normal wound healing76,77. Following normal repair, 
myofibroblasts usually undergo apoptosis, but in pathological states, they persist 
within a milieu of elevated TGF-β1 to promote fibrosis78-80. Coordinated increases 
in TGF-β1, fibroblasts, and collagen were observed with a porcine model of cardiac 
remodeling caused by ischemia-reperfusion injury81. In patients undergoing 
coronary artery bypass after myocardial infarction, cardiac biopsies in proximity to 
the infarcts also revealed elevated TGF-β1 protein expression and mRNA in 
fibroblasts and macrophages82. Perhaps chronic ischemia-reperfusion injury in 
PAD also produces an increase in TGF-β1 that promotes myofibrosis.  
Although not well studied in skeletal muscle, animal models of Duchenne 
Muscular Dystrophy and Marfan Syndrome have shown associations among TGF-
β1 expression, myofibroblast activation, and myofibrosis83,84. In addition to 
fibroblasts, TGF-β1 can also induce transition of other cells into myofibroblasts85,86. 
In kidney and lung, TGF-β1 induces epithelial-to-mesenchymal 
transdifferentiation87-89. In liver, TGF-β1 induces pericytic stellate cells to transform 
into myofibroblasts, which accelerates liver cirrhosis90. More recently, others have 
shown that TGF-β1 induces endothelial-to-mesenchymal transdifferentiation that 
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increases the number of myofibroblasts in the heart and various other organs91-94. 
Although the mechanism by which TGF-β1 promotes fibrosis is being actively 
researched, cellular sources of TGF-β1 remain largely understudied.  
Immune cells such as macrophages express TGF-β1 during fibrogenesis. 
Macrophages are innate immune cells that participate in inflammatory responses 
against pathogens, but are also intimately involved in responses to sterile injury, 
such as during chronic ischemia-reperfusion95. Depending on the cytokine 
environment mediated by specific T helper cells (pro-inflammatory Th1 and anti-
inflammatory Th2), macrophage activation states range from a pro-inflammatory 
classical M1 phenotype to an anti-inflammatory alternative M2 state that promotes 
wound healing and follows resolution of inflammation96. Each phenotype is 
activated by specific Th1 and Th2 cytokines and in turn, produces specific 
cytokines. For example, IL-4 from Th2 can activate an M2 phenotype that produces 
IL-10 and TGF-β1 and is associated with fibrosis. Indeed, co-culture experiments 
with M2 cells that express elevated TGF-β1 and human fibroblasts demonstrated 
fibroblast proliferation and collagen synthesis96. In mouse models of cirrhosis97 and 
renal fibrosis98, a Th2 environment increased TGF-β1-expressing M2 cells that 
enhanced liver and renal fibrosis. Similarly, in patients with pulmonary fibrosis, 
alveolar macrophages exhibited an M2 phenotype that mediated collagen 
production by normal lung fibroblasts99. Although not well studied in skeletal 
muscle, fibrosis in a DMD mouse model was accompanied by increased numbers 
of M2 cells, TGF-β1 expression, and myofibroblasts activation100,101. Taken 
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together, these findings indicate macrophages may be the predominant cell type 
activated by chronic ischemia-reperfusion injury to induce pathological fibrosis.  
Compared to immune sources of TGF-β1, vascular sources have not been 
well investigated. Rather, focus has been on how TGF-β1 signals vascular cells to 
mediate fibrosis102, in hopes of developing anti-fibrotic therapies that block TGF-
β1 receptors or its downstream signals in specific cell types. Such an approach, 
however, may overlook important vascular sources that continue to secrete TGF-
β1, whose pleiotropic effects on many cell types may be difficult to modulate or 
prevent. This may explain the lack of successful TGF-β1 based anti-fibrotic 
therapies. Although TGF-β1 has been reported in vascular smooth muscle cells, 
myofibroblasts, and endothelial cells with vascular remodeling72-74, vascular 
smooth muscle cells are the most plausible contributor to TGF-β1-mediated end-
organ fibrosis in PAD.  
Vascular smooth muscle cells can transition between a spindle-shaped 
contractile form to a cobblestone synthetic one capable of secreting extracellular 
matrix during vascular injury and atherosclerosis76,77,103. In such a context, it is 
possible that vascular smooth muscle cells upregulate TGF-β1 in response to 
chronic ischemia-reperfusion injury. Studies of human varicose veins, where 
remodeling also occurs, show increased TGF-β1 in vascular smooth muscle cells 
with age104, which may not only contribute to venous insufficiency, but also end-
organ fibrosis. If vascular smooth muscle cells indeed contribute to myofibrosis in 
PAD skeletal muscle, their phenotypes may be modulated towards the contractile 
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form to reduce or prevent fibrosis76. This may, in turn, have beneficial effects on 
the myofibers themselves, given that fibrosis physiologically and biologically 
prevents the regeneration of myofibers. Additionally, TGF-β1 can induce abnormal 
remodeling within vessels105, which may compromise blood-flow mechanics, 
oxygen and nutrient distribution, and increase oxidative stress and mitochondrial 
dysfunction, all of which produce myofiber necrosis16,53. 
TGF-β1 may further promote fibrogenesis indirectly by inhibiting skeletal 
muscle regeneration in PAD106. The earliest study found, in culture, that TGF-β1 
directs myoblasts to differentiate into fibrotic cells rather than myogenic cells and 
that when these cells were transplanted into whole muscle in mice, differentiates 
into myofibroblasts107. Furthermore, injection of TGF-β1 into healthy skeletal 
muscle of mice induces myoblasts to upregulate TGF-β1 and produce fibrosis 
within the injected area, and mouse skeletal muscle injured by laceration also 
contained myoblasts with increased TGF-β1 expression107. Later studies showed 
that TGF-β1 regulates the regenerative capacity of skeletal muscle. In mice that 
were subjected to freeze-injury of their skeletal muscle, regeneration became 
increasingly abnormal the longer TGF-β1 expression was upregulated in the 
muscle108. In rats, addition of neutralizing antibodies against TGF-β1 to platelet-
rich plasma significantly reduced fibrosis and increased muscle regeneration, via 
prolonged satellite cell activation, when injected into sites injured by cardiotoxin109. 
Conditional overexpression of TGF-β1 in mouse skeletal muscle corroborates, 
demonstrating both increased endomysial fibrosis and myofiber atrophy110. Taken 
together, reducing the elevated levels of TGF-β1 in PAD skeletal muscle may not 
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only prevent or reverse fibrosis, but also induce regeneration, marked by 
increasing size of myofibers.  
The increased expression of TGF-β1 in the gastrocnemius of PAD patients 
promotes myofibrosis, but through which cells types and by which cell types 
remains unknown. The myopathy that develops in PAD is initially caused by 
changes first experienced by the vasculature and thus, the vascular-myofiber 
interface may be where TGF-β1 is upregulated. In the context of atherosclerosis 
and its associated fibrosis, the most likely candidate would be vascular smooth 
muscle cells. However, in many myopathies, immune cells such as macrophages 
secrete elevated levels of TGF-β1 to promote fibrosis. With ischemia-reperfusion 
injury to PAD muscle, monocytes may be recruited and secrete TGF-β1 to induce 
fibrosis. Furthermore, the cell types that are activated by TGF-β1 to secrete the 
excessive amounts of extracellular matrix have not been well characterized in the 
skeletal muscle of PAD patients, although the classical fibroblast is likely to be the 
major cell type. Finally, the anti-regenerative effects of TGF-β1 may present 
additional barriers to normal repair following chronic ischemia-reperfusion injury 
that contributes to myofiber degeneration that paves the way for replacement by 
scar tissue in PAD skeletal muscle.  
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Diagnosis and Management of Peripheral Artery Disease 
A detailed history and physical examination are necessary for the early 
detection of PAD that is critical for proper disease management. In addition to 
family history, risk factors, and symptoms of claudication, blood pressure 
measurements are performed on the arms and ankles to confirm the diagnosis of 
PAD. If the ratio between blood pressures in the ankle divided by those in the arm, 
known as Ankle-Brachial Index (ABI) is equal to or less than 0.90, there is a high 
sensitivity (90%) and specificity (98%) that the patient has PAD111. However, often 
times the ABI remains in the normal range, despite the presence of atherosclerosis 
in arteries supplying their lower limbs. Physical examination and ABI 
measurements of the patient while walking on a treadmill is then used to diagnosis 
PAD. If the ABI decreases by at least 20%, then they have PAD and are referred 
to vascular specialists who then perform imaging tests111. Based on the severity of 
the symptoms, duplex ultrasound, computed tomographic angiography, magnetic 
resonance angiography, and contrast angiography are performed to localize and 
determine the extent of the vascular blockages112. Failure to consider the history 
of the patients and risks factors for atherosclerosis often leads to the 
underdiagnosis of Fontaine stage I PAD patients who do not present with 
claudication. Early diagnosis is important to proper management, which may 
prevent exacerbation of ischemia-reperfusion to the legs, and the initiation of 
myopathy in the limbs of PAD patients, and preserve limb function.  
Multiple modalities exist for the management of PAD patients. Patients are 
monitored by continual ABI measurements, which are known to correlate with 
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increasing Fontaine stages and declining limb function113,114. Imaging studies can 
determine the rate at which the atherosclerotic plaque is expanding. Both ABI and 
imaging can also be used to monitor the response of patients to therapies that 
include cardiovascular risk reductions related to lifestyle choices, medications, 
exercise therapy, and revascularization procedures115,116. Most PAD patients are 
treated medically by addressing risk factors, medication, and exercise training to 
manage the symptoms of claudication that allow patients to walk better. Diet and 
exercise in addition to cholesterol lower drugs like statins, better control of diabetes 
and hypertension, and quitting tobacco are examples of the recommendations to 
reduce risk factors. Additionally, two federally approved drugs, cilostazol and 
pentoxifylline, are commonly prescribed to alleviate claudication symptoms as they 
either dilate the arteries, decrease blood viscosity, or decrease platelet 
aggregation, all of which improves flow. However, these drugs do not directly target 
atherosclerosis or the myopathy. Despite these management efforts, many PAD 
patients still develop incapacitating claudication and they become candidates for 
revascularization procedures. As evident, the treatment algorithm for PAD patients 
focus on preventing or decreasing the symptoms, with none of them curing the 
disease115,116. However, supervised exercise and revascularization procedures are 
interventions that demonstrate robust improvements in limb function. Yet, in the 
long run limb function of patients often still declines and it is unknown how either 
intervention affects the myopathy that develops in the limbs of PAD claudicants.  
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Revascularization Improves Limb Function in PAD Patients 
            Interventional procedures aimed at restoring blood flow to the lower limbs 
have been well established to improve the limb function of PAD patients who 
present with critical limb ischemia or have claudication that significantly interferes 
with their quality of life. Revascularization can be achieved with open bypass 
surgery, where vein grafts are connected proximally and distally to the site of 
blockage117. Alternatively, endovascular procedures that include percutaneous 
balloon angioplasty and/or stenting can improve the patency of arteries118. Two of 
the most commonly assessed walking performance parameters are the six-minute 
walking distance (SMWD) and peak walking time (PWT). Each measures different 
aspects of limb function under conditions and have been used to study the effects 
of interventions113,114. Although revascularization increases both SMWD and PWT 
in PAD patients, the improved performance is often short-lived, and over a few 
years begins to decline. This may be because revascularization prevents further 
ischemia-reperfusion from injuring PAD muscle, but cannot reverse the myopathic 
changes that have already occurred. However, no study has examined how 
revascularization affects myopathic changes in PAD muscle.  
            Improvements in limb function following revascularization have been 
measured on treadmill. The classic protocol developed by Gardner-Skinner is 
standardly used and occurs in a very controlled environment119. PAD patients start 
walking on treadmill at 2 mph (3.2 km/hr) at a zero-degree incline, or grade. This 
work rate is typical of low-intensity activities of daily life that elderly patients would 
experience and is well tolerated by the vast majority of PAD patients. Then, every 
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2 minutes, the grade is increased by 2% by increasing the incline angle and this 
occurs until the patient becomes limited by maximally tolerated claudication 
symptoms. The longest time PAD patients can walk on this graded treadmill test is 
defined as the PWT. Thus, the walking velocity, and rate of increase in walking 
speed and intensity are highly regulated and as a consequence, the reproducibility 
is very high and variability is low120. Moreover, placebo effects, where performance 
in PAD patients is improved in the absence of interventions, is also not 
appreciable, ranging from 13% to 23% in 6 months121.  
PWT, therefore, is the typical primary outcome in clinical trials evaluating 
therapies, such as revascularization, that improve walking impairment122. One 
such study was CLEVER, which was a multi-centered randomized clinical trial of 
claudicating PAD patients. In that study, those who underwent endovascular 
revascularization procedures (41 patients) significantly improved their PWT by 2.5 
minutes at 6 months compared to optimal medical treatment alone (18 patients), 
an improvement that endured at 18 months follow-up123,124. Similarly, 
revascularization by bypass surgery demonstrated a 5.6-minute increase in PWT 
in 14 PAD claudicants, but there was no sham operated control group for 
comparison due to obvious ethical reasons29. Other studies corroborate these 
findings, but measured maximal walking distance instead125-127. However, this is a 
surrogate measure of PWT, since greater distances covered on treadmill correlate 
with longer times. 
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Improvements in limb function following revascularization have been also 
measured by the SMWD test. This inexpensive test is performed under 
submaximal exercise conditions, where PAD patients are instructed to walk back 
and forth along a corridor that is at least 100 feet long and the distance covered is 
measured during six minutes128. Rest is allowed if discomfort and claudicating 
symptoms arise, but time continues to elapse. Like PWT, SMWD is a well validated 
measure of walking endurance and is sensitive to functional declines in PAD 
patients and therapeutic interventions, such as revascularization129. However, 
unlike PWT, SMWD is measured in an environment that more closely resembles 
walking in daily life128,129 and predicts mobility loss and mortality130,131. Additionally, 
a minimally clinically important difference in SMWD of 30 meters has been 
established, albeit from studies of chronic lung disease, while it is more difficult to 
translate differences in PWT to clinical benefits129. However, SMWD has been 
criticized for being susceptible to environmental and intervention-independent 
factors because it is an endurance test under submaximal exercise conditions with 
no fixed physiological correlate132. Other disadvantages are that SMWD has been 
studied less in PAD patients compared to PWT and so factors such as applicability 
to a wide range of patients, and baseline values have not been well established132. 
As a result, SMWD data for revascularization intervention has only recently 
surfaced. 
To date, only two studies have examined SMWD before and after 
revascularization and found significant improvements. In the first study, 153 PAD 
patients received percutaneous transluminal angioplasty followed by stenting133. 
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The SMWD measured at baseline was 84.1 meters and significantly increased to 
348 meters 6 months after revascularization. The ABI also significantly increased 
from about 0.5 to 1.0 in both limbs133, a finding consistent with revascularization 
studies that measured PWT on treadmill as the endpoint123,124. The second study 
performed only angioplasty on 47 PAD patients and also found significantly 
improved function 6 months out, but by 12 months had declined below baseline134. 
As evident from these studies, SMWD can be used to measure improved limb 
function following revascularization and to determine if they last over time. In 
conjunction with PWT, SMWD may provide additional insights into the functional 
limitations of PAD patients, given SMWD only demonstrates a weak correlation 
with PWT (r2 = 0.28)135. Similar studies have not been done for open bypass 
surgery because in the past decade, first line therapy has shifted from bypass 
surgery to endovascular interventions, which is less invasive with lower risks, and 
applicable to the majority of PAD patients who are indicated for revascularization. 
The mechanism by which revascularization improves limb function is by 
restoring blood flow, but its effects on myopathy in the PAD limb remains largely 
unknown. Open bypass surgery and endovascular procedures acutely increases 
ABI, reduces ischemic leg symptoms, and immediately improves walking 
distance136. Thus, revascularization alleviates chronic ischemia-reperfusion injury 
to the limb and would be expected to improve or at least inhibit progression of 
myopathic changes, such as oxidative damage, mitochondrial dysfunction, 
myofiber degeneration, and fibrosis. It is important to determine this because 
defects not addressed by revascularization need to be targeted by novel 
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therapeutic strategies aimed at maintaining and further improving the walking 
abilities of PAD patients, especially those who are contraindicated for 
revascularization due to co-morbidities or overall health status.  
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Supervised Exercise Improves Limb Function in PAD Patients 
            Before PAD patients become candidates for revascularization, they are first 
prescribed exercise regimens that have been well established to relieve 
claudicating symptoms and improve functional status in PAD patients137. Other 
considerations for this recommendation include the risks associated with bypass 
surgery and endovascular procedures and the frequency with which restenosis of 
the arteries occur, as early as 6 months following revascularization138. Two types 
of exercise programs exist, unsupervised and supervised, and it has been 
established that supervised regimens, consisting of walking 3 times a week for 30-
60 minutes over 12 weeks on treadmill, improves the walking ability of PAD 
patients better than unsupervised programs139. Reasons include lack of adherence 
and patients not performing the exercises properly to attain the maximal benefits. 
Supervised exercise therapy, however, is expensive and not covered by Medicare 
and insurance plans and is often cumbersome since patients have to travel to sites 
multiple times a week. Although supervised exercise improves limb function, the 
improvements are at best maintained short-term and like revascularization, is a 
management strategy and not a cure for PAD patients.  
            Given that exercise therapy is recommended before revascularization, 
more studies have been conducted to determine the impact of exercise therapy on 
limb function and how it directly compares with revascularization. A recent 
systematic review of 30 clinical trials found that compared to standard care, 
supervised exercise improved PWT by 4.51 minutes and maximum walking 
distances on graded treadmill by 109 meters in PAD patients140. Furthermore, 
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these improvements were greatest at 6 months and lasted up to two years140. Only 
two studies have been conducted to measure SMWD in PAD patients before and 
after supervised exercise. The first study was conducted in the United States and 
found that in 156 PAD patients, SMWD significantly increased by 35.9 meters at 6 
months follow-up after supervised treadmill exercise141. A subsequent smaller 
European study of 51 PAD patients reported SMWD to increase by 100 meters 
after 3 months of supervised exercise142. Although follow-up at 6 months still 
revealed a significant increase like the American study, there was a trend towards 
declining function that resulted in performance similar to baseline at 12 months142. 
Thus, improvements in SMWD by exercise therapy may not last beyond six 
months. Two comprehensive systematic reviews have concluded that the ability of 
PAD patients to walk longer and further after supervised exercise is comparable 
to revascularization143,144. A single-site randomized clinical trial published after 
these two systematic reviews corroborates their conclusion. PAD patients were 
followed seven years out and no differences were found in walking distances or 
quality of life between the two interventions145. However, a more recent multi-site 
trial CLEVER reported that supervised exercise was superior to revascularization 
stenting for PWT for at least 18 months123,124, prompting comparisons of exercise 
with revascularization against exercise therapy alone.  
             The few clinical trials that have compared supervised exercise and 
revascularization against exercise alone demonstrated that combination therapy 
was superior for limb function. The ERASE trial studied 212 PAD patients and 
found at 1 year follow-up that combined endovascular procedures with supervised 
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exercise increased the treadmill walking distance on the graded treadmill test 
significantly more than supervised exercise alone, by 282 meters127. An earlier 
study MIMIC randomized 127 patients to similar groups, with angioplasty as an 
adjuvant therapy for PAD patients who were already partaking in supervised 
exercise programs146. Compared to supervised exercise alone, combination 
therapy produced significantly greater maximal treadmill walking distance at 6 
months when the supervised exercise ended, and the improvements were 
maintained at 2 years146. However, other studies put into question how long the 
improved limb function lasts. A trial that studied 178 PAD patients found that 
combined exercise and angioplasty increased PWT significantly more than 
exercise therapy alone at 3 months, but there were no differences at 12 months126. 
Overall, the benefits of combined therapy versus exercise alone probably 
represent the best improvements for PAD patients at approximately 6 months. 
Benefits are largely maintained up to 2 years, but does not progressively improve 
throughout that period of time, pointing to the need for adjunct therapies. Adjunct 
therapies are also especially needed, since PAD patients with co-morbidities or 
overall poor health are precluded from either supervised exercise or 
revascularization, thus limiting the maximal benefit that they can achieve in walking 
performance. A better understanding of the mechanisms by which exercise 
improves limb function and how it affects the developing myopathy in the limbs of 
PAD patients may provide novel paths towards such adjunct therapies.   
The mechanisms by which exercise therapy improves the walking abilities 
of PAD patients are distinct from revascularization and are not as well 
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characterized. Unlike the immediate functional improvements seen with 
revascularization, supervised treadmill exercise improves performance gradually, 
with the earliest benefits at approximately 1 to 2 months136. Despite these 
improvements, the blood flow does not improve. A systematic review of 33 clinical 
trials found that exercise therapy did not increase the ABI140, which demonstrates 
that the mechanisms of supervised exercise on limb function are not directly blood 
flow dependent. The following theories have been implicated by exercise studies 
of PAD patients.  
In healthy people, exercise training induces an array of adaptations that 
include increased muscle mitochondrial content, improvements in the ability to 
generate energy with the amount of oxygen that is delivered, increased perfusion 
of blood in the microcirculation, and improved walking economy132. This increased 
metabolic efficiency may improve the mitochondrial dysfunction and oxidative 
stress found in the muscle of PAD patients. Studies in PAD patients following 12 
weeks of supervised exercise have shown that the oxidative capacity of calf 
skeletal muscle was increased, whereby greater oxygen extraction per unit of 
blood occurred147. In patients who completed 12 weeks of treadmill training that 
intentionally produced claudication pain, the buildup of Kreb cycle components 
decreased, indicating improved muscle metabolism48. Similarly, the increased 
blood perfusion that results from exercise training in healthy individuals may allow 
the blood that does arrive to the lower limb move more efficiently into the muscle. 
In PAD patients, exercise-induced angiogenesis and enhanced nitric oxide-
dependent vasodilation in endothelia of the microcirculation, and decreased blood 
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viscosity have all been demonstrated148,149. The increased efficiency of blood to 
the muscle, coupled with improved oxygen extraction and muscle metabolism, may 
underlie the improved walking economy of PAD patients following supervised 
exercise therapy. After four months of exercise training, PAD patients use less 
oxygen at a given workload150 and this biomechanical efficiency likely translates 
into improved walking performance. It may be that exercise reverses the oxygen 
cost created by the gait abnormalities that patients adopt in response to leg pain, 
mainly those that favor increased stability at the expense of velocity151-154. 
Much less well studied are the effects of exercise therapy on systemic and 
local inflammation and fibrosis in the muscle of PAD patients, which are the 
reparative defects produced by chronic ischemia-reperfusion injury65. One study 
found that exercise training improved claudication symptoms and concomitantly 
reduced inflammatory markers in the circulation, such as C-reactive protein155. 
Inflammatory markers in the leg muscle may also be altered to promote resolution 
of chronic inflammation and pathological fibrosis. More research is needed to know 
how all the physiological benefits of exercise specifically extend to PAD myopathy. 
For example, peripheral nerve function is improved following exercise therapy, but 
it is unclear how this may affect the myopathy. The potential mechanisms by which 
exercise therapy improve limb function are summarized in Figure 1.4. Overall, how 
the biological mechanisms improved by supervised exercise therapy directly relate 
to the myopathy present in the legs of PAD patients is unclear. What is clear 
though, is that understanding how supervised exercise affects PAD myopathy will 
point to novel therapeutic targets that improve limb function of PAD patients.  
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Figure 1.4: Schema of Potential Mechanisms Underlying the Benefits of 
Exercise Therapy on Walking Performance in Peripheral Artery Disease. 
Obtained from the European Society of Cardiology Online Article “Exercise 
Therapy for Intermittent Claudication in Peripheral Artery Disease. 
http://www.escardio.org/Guidelines-&-Education/Journals-and-publications/ESC-
journals-family/E-journal-of-Cardiology-Practice/Volume-13/exercise-therapy-for-
intermittent-claudication-in-peripheral-artery-disease 
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Hypothesis and Specific Aims 
            Based on data from the literature regarding the pathophysiology of PAD, it 
is clear that a myopathy develops in the lower limb skeletal muscle of these 
patients and causes limb dysfunction. Various components of this myopathy, such 
as oxidative stress, mitochondrial dysfunction, and myofiber degeneration have 
been characterized, while others, such as fibrosis, have not. Although increased 
extracellular matrix in the lower limb skeletal muscle of PAD patients has been 
described by our laboratory and others, the etiology of its development is unknown, 
such as which biological factors play an important role and its pathobiological link 
to atherosclerosis. The robust increase in TGF-β1, a potent inducer of fibrosis, in 
the gastrocnemius of PAD patients was greater than other cytokines and also 
greater than TGF-β1 in serum, both of which suggest its critical role in promoting 
myofibrosis locally in the muscle. In various organs, fibrosis is highly detrimental 
to function. Altering the development of myofibrosis may be a mechanism by which 
the standard therapies, revascularization and supervised exercise, are improving 
limb function. The following hypotheses and specific aims were developed to 
determine if local hemodynamic changes produce a TGF-β1 associated 
myofibrosis and whether or not this myofibrosis is targeted by revascularization 
and exercise therapies to improve limb function in PAD patients.   
The overall hypothesis is that decreased hemodynamics is tightly 
linked to a local TGF-β1 associated increase in collagen deposition within 
the gastrocnemius of PAD patients that increases with disease severity, and 
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that this myofibrosis is reversed by revascularization but not exercise 
therapy in association with improved limb function. We propose that the 
etiology of myofibrosis in PAD is from hemodynamic changes that are directly a 
part of the pathophysiology of PAD, rather than solely as a consequence of 
myofiber degeneration, characteristic of other myopathic diseases. Furthermore, 
the myofibrosis that develops will be dependent on the extent of atherosclerosis 
and hemodynamic state of the limb and not pathological systemic changes that 
are associated with PAD. Finally, revascularization procedures that directly 
improve hemodynamics will reduce expression of TGF-β1 and collagen deposition 
in the gastrocnemius of PAD patients. Exercise therapy, on the other hand, is not 
expected to decrease TGF-β1 associated myofibrosis, since it does not directly 
alleviate compromised hemodynamics. Addressing this hypothesis will provide 
insight into the natural history of PAD myopathy and response to standard 
therapies, as well as strategies that directly target development of myofibrosis to 
maintain or improve limb function in PAD patients.  
This hypothesis will be tested by implementation of three specific aims that 
determine 1) the presence and etiology of a TGF-β1 associated myofibrosis, 2) 
whether myofibrosis represents a local response to ischemia or a response to 
systemic events and 3) how revascularization and exercise therapy affect the 
progression of this TGF-β1 associated myofibrosis in relation to limb function.  
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Specific Aim 1: Investigate the relationships among limb 
hemodynamics, and both TGF-β1 expression and collagen deposition in the 
gastrocnemius of PAD patients at advancing disease stages to establish the 
presence and potential etiology of myofibrosis. Using multi-spectral 
microscopy (MSM) of gastrocnemius specimens stained with Masson Trichrome, 
we measured collagen density and area to determine the extent of fibrosis in 
gastrocnemius biopsies of PAD patients at Fontaine Stage II and Fontaine Stage 
IV stages of disease compared to age-matched control patients. Expression of 
TGF-β1 in the same patient groups was measured by quantitative fluorescence 
microscopy (QFM) after immunofluorescence labeling for TGF-β1. Co-localization 
studies using specific markers for vascular and immune cells was used to 
determine the cellular source of TGF-β1 expression that is indicative of the etiology 
of myofibrosis. Immunohistochemistry for expression of TE-7 positive fibroblasts 
further explored the mechanism of myofibrosis, whereby increased TGF-β1 
expression activates fibroblasts to deposit extracellular matrix to promote 
pathological fibrosis. The hemodynamic state of the limbs from which biopsies 
were obtained was measured as the Ankle-Brachial Index (ABI). Correlational 
analyses were performed among ABI, TGF-β1 expression, and collagen density to 
determine if a TGF-β1 associated myofibrosis exists and whether or not it is 
associated with reduced hemodynamics in the lower limb of PAD patients.    
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Specific Aim 2:  Determine whether TGF-β1 associated myofibrosis in 
the gastrocnemius of PAD patients is a localized response in the ischemic 
muscle or response to systemic events. The previous aim established that 
myofibrosis in the gastrocnemius of PAD patients is associated with increased 
TGF-β1 expression of vascular origin, leaving the possibility that the observed 
myofibrosis is induced by circulating factors related to atherosclerosis in addition 
to local hemodynamic changes produced by atherosclerosis. Gastrocnemius 
biopsies were obtained from both limbs of Fontaie Stage II PAD patients with 
unilateral disease, who had significantly greater atherosclerosis in the diseased 
compared to contralateral limbs as reflected by the signifiantly lower ABI. Biopsies 
were assessed for TGF-β1 expression at the protein level by QFM and transcript 
level by qPCR, and for collagen density by MSM. Correlational analyses were 
performed between the limbs for the expression of TGF-β1 and collagen density. 
Furthermore, correlational analyses between TGF-β1 expression and collagen 
density were performed separately in the diseased and contralateral limbs. Greater 
myofibrosis in the diseased compared to contralateral limb, with no relationships 
between the limbs would indicate a local response to atherosclerosis as the 
etiology, while no difference in myofibrosis between the limbs and a direct 
relationship between the limbs would indicate that systemic contributions exist.   
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Specific Aim 3: Determine changes in myofibrosis in relation to limb 
function, hemodynamics, and myofibers size, in PAD patients who have 
undergone revascularization or exercise therapy. Revascularization and 
supervised exercise are standard therapies that improve limb function in PAD 
patients but whether or not it is by improving the TGF-β1 associated myofibrosis 
is unknown. Fontaine Stage-II PAD patients underwent revascularization by open 
bypass surgery or endovascular procedures that involved balloons and/or stents, 
or participated a supervised exercise therapy program for 6 months. Biopsies were 
obtained at baseline and 6 months. Limb functional assessments were also 
performed at those time points. Six Minute Walking Distance (SMWD) and Peak 
Walking Time (PWT) were measured. Additionally, ABI and morphometric analysis 
for myofiber size was determined. Correlational analyses were performed among 
TGF-β1 expression, collagen deposition, SMWD, PWT, ABI, and myofiber size. A 
subset of patients received no intervention and served as a control for direct 
comparison against revascularization and exercise therapies. 
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CHAPTER II: TGF-β1 ASSOCIATED MYOFIBROSIS DEVELOPS WITH 
INCREASING PAD DISEASE SEVERITY AND IS ASSOCIATED WITH 
REDUCED HEMODYNAMICS  
Introduction 
Lower leg ischemia, myopathy and limb dysfunction are distinguishing 
features of Peripheral Artery Disease (PAD) caused by atherosclerotic blockages 
of the arteries supplying the legs. The myopathy in the affected legs of PAD 
patients is characterized by myofiber degeneration, elevated pro-fibrotic cytokines, 
and increased fibrosis35,36,44,54,156,157. In Chapter I, the development of myofibrosis 
with increasing PAD disease stage was suggested by observations on computed 
tomography and hematoxylin and eosin histology of the gastrocnemius of PAD 
patients at Fontaine Stage II and IV compared to age-matched controls (Figure 
1.3). Cytokine profiling of gastrocnemius homogenates from Fontaine Stage-II 
PAD patients and age-matched controls revealed that transforming growth factor-
beta 1 (TGF-β1), which is considered the most potent inducer of fibrosis, is the 
most robustly and consistently elevated cytokine in PAD patients (Table 1.1). The 
expression of TGF-β1, however, was not evaluated in Fontaine Stage IV patients 
and its relationship to fibrosis with advancing disease in PAD has not been 
examined. Moreover, the etiology of the increased TGF-β1 is unknown. Chapter II 
explores the relationships between TGF-β1, collagen deposition in PAD patients 
at different disease stages to establish that TGF-β1 associated myofibrosis is part 
of PAD myopathy. Furthermore, we investigate the cellular sources of TGF-β1 in 
relation to ABI limb hemodynamics to gain insight into the etiology of PAD 
myofibrosis. 
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The etiology of myofibrosis in PAD may be immune or vascular. Classically, 
in response to acute injury and inflammation, TGF-β1 is secreted by immune cells, 
such as macrophages and T cells, during the resolution of phase of inflammation 
to reduce inflammation and initiate physiological wound healing73,74. TGF-β1 
inhibits T cells and activates myofibroblasts to deposit extracellular matrix, of which 
a major component is collagen. In many chronic diseases of the muscle, such as 
the dystrophies, TGF-β1 is highly elevated and persistently activates 
myofibroblasts to deposit excessive extracellular matrix around the myofibers and 
associated microvessels which interferes with oxygen and nutrient delivery, 
producing myofiber degeneration70,71,158,159. Additionally, TGF-β1 can inhibit 
regeneration in skeletal muscle to promote PAD myopathy by inducing myoblasts 
to differentiate into myofibroblasts rather than new myofibers70,71,158,159. In this 
setting, it has been demonstrated that TGF-β1 is produced by immune cells to 
induce pathological fibrosis69-71.  
However, other cells besides immune cells have also been reported to 
upregulate TGF-β1 expression and contribute to fibrosis in various organ systems, 
and these include vascular cells67,72,160-162. For example, in pulmonary arterial 
hypertension (PAH), vascular smooth muscle cells (SMC) transition from a 
contractile to a synthetic phenotype that produces TGF-β176,77,163,164. In PAH, 
chronic hypoxia induces substantial thickening of vascular intima, media and 
adventitia caused by extensive proliferation and hypertrophy of vascular SMC that 
exhibit increased expression of TGF-β1, and deposition of extracellular matrix; 
features that extend to normally non-muscularized microvessels164,165. In the 
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context of PAD, vascular cells may contribute to the expression of TGF-β1, since 
PAD is a chronic disease originating from the arteries. A similar transitioning of 
vascular SMC may be occurring in response to exercise-induced ischemia and the 
chronic intermittent hypoxia that are caused by atherosclerosis of the large vessels 
supplying the legs. If that is true, we expect this transitioning to also be related to 
the degree of hemodynamic compromise of the affected extremity and the clinical 
stage of PAD.  
This study addresses Specific Aim 1 by evaluating the cellular expression 
of TGF-β1 in the gastrocnemius of control and PAD patients with advancing 
Fontaine Stage, and its relationship to deposited collagen, fibroblast accumulation, 
and Ankle-Brachial Index (ABI). We hypothesize that there is a TGF-β1 associated 
myofibrosis that is increased with PAD severity and is of vascular origin, whereby 
TGF-β1 is expressed by vascular cells and inversely correlates with ABI.  
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Methods 
Characteristics of Human Subject Groups 
The experimental protocol was approved by the Institutional Review Boards 
of the Veterans Affairs Nebraska-Western Iowa and University of Nebraska 
Medical Centers. All subjects gave informed consent.  
PAD Groups: We recruited 25 Fontaine Stage-II PAD patients (PAD-II) and 
20 Fontaine Stage-IV patients (PAD-IV). PAD-II patients presented with 
intermittent claudication, but no rest pain or tissue loss. PAD-IV patients presented 
with non-healing ulcers and/or gangrene and had lower extremity operations. 
Diagnosis for each patient was established on the basis of medical history, 
physical examination, decreased ankle brachial index (ABI < 0.9), and 
computerized or standard arteriography that revealed stenotic and/or occluded 
arteries supplying the lower extremities.  
Control Group: We recruited 20 control patients (CTRL) who were 
undergoing lower extremity operations for indications other than PAD. Control 
patients led sedentary lifestyles with no history of PAD symptoms and had normal 
blood flow to their lower limbs, as indicated by normal lower extremity pulses at 
examination, and normal ABI at rest and after exercise.  
Patient Demographics: Data for CTRL, PAD-II, and PAD-IV patients are 
presented in Table 2.1. On average, PAD-IV patients were 6 years older than 
PAD-II (p = 0.047) and 8 years older than CTRL (p = 0.006) patients. More PAD-
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IV patients had diabetes than PAD-II and CTRL patients (χ2 = 5.55, p = 0.006; 
both p < 0.05). Age and diabetes were treated as covariates in all subsequent 
statistical analyses.  
Biopsy and Histological Preparation 
Gastrocnemius samples weighing approximately 250 mg were obtained 
from the anteromedial aspect of the muscle belly, 10 cm distal to the tibial 
tuberosity. All biopsies were obtained with a 6 mm Bergstrom needle. Some of the 
samples were frozen in liquid nitrogen for biochemical analysis while others were 
placed immediately into cold methacarn. After 48 hours, the specimens were 
transferred to cold 50% ethanol, and subsequently embedded in paraffin. 
Quantitative Assessment of Collagen Deposition 
Masson Trichrome Stain: Paraffin-embedded biopsies sectioned at 4 
microns were stained with a Masson Trichrome Kit according to manufacturer’s 
protocol (Fisher Scientific Richard Allan Scientific #22-110-648, Pittsburg, PA, 
USA). Briefly, slide specimens were deparaffinized in xylene, hydrated and then 
incubated at room temperature in Bouin’s fixative for 16 hours. Nuclei were stained 
with Weigert’s Hematoxylin, myofiber cytoplasm with Scarlet Red, and collagen 
with Aniline Blue dye, with washes in-between steps. Stained slide specimens 
were dehydrated and mounted with Permount (Fisher Scientific #SP15-100, 
Pittsburg, PA, USA).  
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 CTRL PAD-II PAD-IV p-value 
Number of Patients 20 25 20 N/A 
Mean Age (years) 62.1 ± 5.40 64.1 ± 7.80 69.9 ± 9.40* 0.011 
Gender (male/female) 19/1 24/1 20/0 0.983 
Height (m) 1.75 ± 0.07 1.76 ± 0.06 1.77 ± 0.06 0.576 
Weight (kg) 91.0 ± 17.4 87.5 ± 18.8 85.0 ± 21.1 0.598 
Body Mass Index 29.9 ± 6.40 28.2 ± 5.16 28.4 ± 6.61 0.593 
Obesity† (%) 45 36 25 0.416 
Smoking (%) 50.0 56.0 30.0 0.202 
Diabetes Mellitus (%) 25.0 20.0 65.0* 0.004 
Dyslipidemia (%) 55.0 80.0 60.0 0.166 
Coronary Artery Disease (%) 20.0 36.0 35.0 0.701 
Myocardial Infraction (%) 0.00 8.00 0.00 0.192 
Hypertension (%) 65.0 84.0 90.0 0.116 
Statins Medication (%) 70.0 84.0 65.0 0.317 
Renal Insufficiency
‡ (%) 5.00 12.0 20.0 0.352 
Ankle Brachial Index
§ 
(Minimum – Maximum) 
1.04 ± 0.11* 
(0.79–1.20) 
0.55 ± 0.22* 
(0.10–0.95) 
0.22 ± 0.13* 
(0.00–0.44) 
<0.001 
 
Table 2.1: Demographics of Study Groups157. 
 
† Obesity: Body mass index > 30 
‡ Renal Insufficiency: Creatinine clearance < 60 ml/min/1.73m2 
§ABI: Data presented as Mean ± Standard Deviation 
 
CTRL = Controls, PAD-II = Fontaine Stage II, PAD-IV = Fontaine Stage IV 
* p < 0.05 versus other two groups by post-hoc Bonferroni adjusted t-tests 
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Image Acquisition and Multi-Spectral Microscopy: Microscopic fields of the 
five most fibrotic regions were collected from each Masson Trichrome stained slide 
(20x objective). Muscle tissue completely filled each chosen microscopic field. 
Imaging was implemented by multispectral wide-field microscopy, using a Leica 
microscope (North Central Instruments DMRXA2 Model, Plymouth, MN, USA) 
coupled with the Nuance EX Multispectral Imaging System (PerkinElmer N-MSI-
EX Model, Waltham, MA, USA) that incorporates a CCD camera and liquid crystal 
tunable filter. This system generates an absorbance spectrum at each pixel of a 
two-dimensional spatial image of the specimen. The Nuance software 
quantitatively extracts the grey scale image of deposited collagen, which is then 
transferred to the Image-Pro® Plus image analysis software (Media Cybernetics, 
Warrendale, PA, USA) for quantification of collagen area and density. Collagen 
density was determined as area-weighted mean pixel intensity (12-bit grey scale). 
Quantitative analysis was performed blinded from the group status. Figure 2.1 
depicts the processing of one representative region of interest. 
 
 
 
 
 
 
67 
 
 
Figure 2.1: Multi-Spectral Microscopy of a Representative Fibrotic Region of 
PAD Patient Gastrocnemius157. (A) Slide specimens were stained for Masson 
Trichrome, which labels collagen blue, myofiber cytoplasm red, and nuclei black. 
Fibrotic regions of muscle were image and Nuance Software generated a spectral 
library containing each component. (B) Each component was extracted as grey 
scale images. (C) The gray scale image for collagen was inverted in ImagePro 
Plus Software and intensity of labeling was measured as collagen density, while 
collagen area is the number of pixels analyzed (red). 
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Validation of Spectral Analysis: Spectral analysis was validated by the 
hydroxyproline assay for collagen content of human gastrocnemius specimens166. 
Four PAD-IV, three PAD-II, and three CTRL subjects were selected for analysis 
based on their wide range of collagen density determined by wide-field multi-
spectral microscopy. Briefly, approximately 10 mg of liquid nitrogen preserved 
gastrocnemius muscle from each patient was hydrolyzed in hydrochloric acid 
(Fisher Scientific #SA56-1, Pittsburg, PA, USA) overnight for 12 hours at 130° C. 
Then, contents were adjusted to neutral pH by potassium hydroxide (Sigma 
#C9887, St Louis, MO, USA) using a solution of phenolphthalein (Sigma #34607, 
St Louis, MO, USA) as indicator, and buffered with Sodium Borate that is 
composed of Sodium Hydroxide (Fisher Scientific #S318-500, Pittsburg, PA, USA) 
and Boric Acid (Fisher Scientific #BP168-500, Pittsburg, PA, USA). Hydroxyproline 
was oxidized by the Chloramine T solution, which is comprised of chloramine T 
(Sigma #C9887, St Louis, MO, USA), citric acid anhydrous (Sigma #C0759, St 
Louis, MO, USA), glacial acetic acid (Fisher Scientific #A38-212, Pittsburg, PA, 
USA), sodium acetate trihydrate (Sigma #S7670, St Louis, MO, USA), sodium 
hydroxide (Fisher Scientific #S318-500, Pittsburg, PA, USA), and 2-mthoxyethanol 
(Sigma #284467, St Louis, MO, USA). Then, the reaction was stopped by Sodium 
Thiosulfate (Sigma #217263, St Louis, MO, USA). Impurities were removed by 
addition of toluene (Sigma #244511, St Louis, MO, USA), inversion and 
centrifugation, and aspiration of the resulting toluene layer. Next, the oxidized 
product was extracted by inversion, centrifugation, and collection of the toluene 
layer. Finally, Ehrlich’s Reagent, a mixture of sulfuric acid (Sigma #339471, St 
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Louis, MO, USA), ethanol (Decon Labs #2701, King of Prussia, PA, USA), and 4-
dimethylaminobenzaldehyde (Sigma #156477, St Louis, MO, USA) was added to 
the extraction to initiate a colorimetric reaction and incubated at room temperature 
for 30 minutes. These samples and hydroxyproline standards (0.0 - 8.0 μg; Sigma 
#H54409, St Louis, MO, USA) were analyzed at 560-nm wavelength on a 
spectrophotometer. The hydroxyproline content of muscle was expressed as μg 
per mg muscle (wet weight). A robust positive correlation (r = 0.907; p < 0.001) 
was detected between hydroxyproline (μg per mg muscle) and optical density from 
spectral images, for 10 patients who encompassed a wide range of collagen 
spectral densities (Figure 2.2A).  
Reproducibility of Spectral Analysis: To determine intersession reliability, 
slide specimens of biopsy samples from 10 patients were stained by Masson’s 
Trichrome in two separate analytical sessions and assessed by spectral analysis. 
The Intraclass Correlation Coefficient (ICC) was estimated by using a two-way 
mixed ANOVA with absolute agreement. An ICC value of less than 0.40 indicates 
poor reproducibility, between 0.40 and 0.75 indicates fair to good reproducibility, 
and greater than 0.75 indicates excellent reproducibility. The ICC (0.865) indicated 
an excellent reproducibility (Figure 2.2B) with an average difference from the 
mean of the two analytical sessions of 4%.  
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Figure 2.2: Validation of Multi-Spectral Microscopic Analysis of Collagen 
Deposition157. (A) Pearson correlation demonstrating the relationship between 
collagen density measurements by multi-spectral microscopic analysis and 
hydroxyproline content in muscle homogenate, as measured by the hydroxyproline 
assay. (B) Reliability of multi-spectral measurements of collagen density in 
independent, analytical sessions A and B was determined as an intraclass 
correlation (ICC) value of 0.865, representing excellent reliability (ICC > 0.75 is 
excellent, 0.75 ≥ ICC ≥ 0.40 is good, and ICC < 0.40 is poor). 
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Quantitative Assessment of TGF-β1 Expression 
Quantitative Fluorescence Microscopy: We describe a novel application of 
quantitative fluorescence microscopy (QFM) to measure TGF-β1 expression in the 
gastrocnemius of PAD patients. QFM is a technique developed by our laboratory 
to measure biomarkers of PAD and prostate cancer 54,167-170.  
Duplicate slide specimens of gastrocnemius biopsies were exposed to a 
rabbit anti-TGF-β1 antibody (2.5 µg/mL; Abcam Ab53169, Cambridge, MA, USA) 
and a mouse anti-CD31 antibody (1:50 dilution; Abcam Ab9498, Cambridge, MA, 
USA; to validate identification of microvessels). Slides were then treated with both 
goat anti-rabbit IgG secondary antibody coupled with Alexa Fluor® 555 and goat 
anti-mouse IgG secondary antibody conjugated with Alexa Fluor® 555 (Life 
Technologies #A21429, Carlsbad, CA, USA). Isotype control slides were treated 
with rabbit IgG (Vector Laboratories #I-1000, Burlingame, CA, USA) and mouse 
IgG1 (eBioscience #14-4714-85, San Diego, CA, USA) at the same concentration 
as the anti-TGF-β1 and anti-CD31 antibodies, respectively. For epitope recovery, 
Tris buffer (pH 9.0) was used. All labeling procedures were performed with a fully 
programmable, robotic autostainer (BioGenex i6000 Model, Fremont, CA, USA). 
The labeled specimens were mounted in ProLong Gold® anti-fade medium 
containing 4’,6-Diamidino-2-phenylindole (DAPI; a nuclear stain) (Life 
Technologies #P36931, Carlsbad, CA, USA). Fluorescence images were captured 
with a Leica epifluorescence wide-field microscope (10x objective) (North Central 
Instruments, DMRXA2 Model, Plymouth, MN, USA) and CCD camera 
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(Hamamatsu Photonics, Orca C4742 Model, Bridgewater, NJ, USA), with 
Hamamatsu software (HCImage 4.0). All fields of each specimen are captured and 
a montage of the gray scale images was generated for analysis with Image-Pro® 
Plus (Media Cybernetics, Bethesda, MD, USA). TGF-β1 positive events in the 
microvasculature are partitioned and both event area and mean pixel intensity are 
determined for each (12-bit grey scale). The sum of the products of area and mean 
pixel intensity of all positive events per microscopic field was computed and 
normalized to the total area of muscle tissue specimen analyzed. Quantitative 
analysis was performed blinded from the group status. Figure 2.3 depicts a 
representative montaged region of interest and its analysis. 
Validation of Quantitative Fluorescence Microscopy: QFM measurements 
of TGF-β1 were validated by comparing results with ELISA and qPCR 
measurements of muscle homogenates from PAD-II and CTRL patients (N=13 in 
each group). Additionally, the TGF-β1 expression patterns were confirmed with a 
second anti-TGF-β1 antibody (Abcam Ab170736, Cambridge, MA, USA). 
ELISA: Conventional sandwich-based ELISA measurements of TGF-β1 
expression in PAD gastrocnemius was carried out according to manufacturer 
instructions as part of a customized Human Inflammatory Cytokine Multi-Analyte 
ELISArray Kit (Qiagen, Valencia, CA, USA). TGF-β1 expression by QFM 
significantly correlated with TGF-β1 by ELISA (r = 0.602; p = 0.001; Figure 2.4A). 
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Figure 2.3: Quantitative Fluorescence Microscopy of a Representative 
Montaged Image of PAD Gastrocnemius157. (A) Slide specimens were labeled 
with TGF-β1 antibody by immunofluorescence and imaged at 10X as individual 
gray scale images that were then montaged into larger regions and transferred into 
ImagePro Plus Software. All vessels were manually selected and the intensity of 
labeling within each vessel was measured as the expression of TGF-β1. (B)  TGF-
β1 expression was normalized to the total myofiber area. (C) The same slide 
specimens were labeled for CD31, a marker of endothelia, to aide in the 
identification of microvessels (thick arrows) from potential artifacts (thin arrows). 
C
 
B
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Quantitative PCR: TGF-β1 RNA transcripts in skeletal muscle biopsies 
stored in liquid nitrogen were extracted, reverse transcribed, and quantified by 
qPCR, as previously described39,171. Levels of TGF-β1 transcripts were then 
normalized to myosin gene transcripts. The following TGF-β1 primers (188 bp, 
NCBI, NM_000660) were used: forward, 5’-CCGCAAAGACTTTTCCCCAGACC-
3’; reverse, 5’- ACCTAGATGGGCGCGATCTGGTA-3’. The following myosin 
primers (199 bp; NCBI, NM_005963) were used: forward, 5’-
TCCGAAAGTCTGAAAGGGAGCGAA-3’; reverse, 5’-
GAGGGTTCATGGGGAAGACTTGGT-3’. TGF-β1 expression by QFM 
demonstrated a significant positive correlation with TGF-β1 transcripts as 
determined by qPCR (r = 0.659; p < 0.001; Figure 2.4B). 
Reliability of Quantitative Fluorescence Microscopy: The intersession 
reliability was determined for TGF-β1 from the averages of patient biopsy 
specimens, analyzed a second time in the next analytical session. The two-session 
mean of each biopsy specimen was determined and each session mean was 
expressed as the absolute difference from the two-session mean. The ICC was 
estimated by a two-way mixed ANOVA with absolute agreement. The ICC (0.993) 
indicated excellent reproducibility (Figure 2.4C), with an average absolute 
difference from the mean of the two analytical sessions of 5.3%. Overall, QFM is 
a reliable method to measure expression of TGF-β1 in skeletal muscle biopsy 
specimens. The intrasession reliability was high (ICC = 0.957), with a 6% average 
absolute difference of each slide from the mean of its duplicate pair. 
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Figure 2.4: Validation of Quantitative Fluorescence Microscopic (QFM) 
Analysis of TGF-β1157. The relationships between TGF-β1 expression 
determined by QFM and TGF-β1 expression determined by (A) ELISA, and (B) 
qPCR in 13 controls and 13 PAD-II patients were analyzed by Pearson correlation. 
(C) Intersession reliability of normalized TGF-β1 values obtained with slides from 
the same patient specimens in two independent analytical sessions A and B was 
determined as an intraclass correlation (ICC) value of 0.918, representing 
excellent reliability (ICC > 0.75 is excellent, 0.75 ≥ ICC ≥ 0.40 is good, and ICC < 
0.40 is poor). 
 
Localization of TGF-β1 Expression by Immunofluorescence 
Individual slides were treated with primary anti-TGF-β1 antibody (Abcam 
Ab53169, Cambridge, MA, USA) and primary antibody specific for each of the 
following cell types. For endothelia, we used an antibody against CD31 (1:50 
dilution) (Abcam Ab9498, Cambridge, MA, USA); for vascular smooth muscle cells, 
an antibody against high molecular weight caldesmon (1 µg/mL) (Abcam Ab1826, 
Cambridge, MA, USA); for fibroblasts, an antibody for TE-7 (1:10 dilution) (Millipore 
78 
 
CBL271, Billerica, MA, USA); for macrophages, antibodies for CD163 (2.5 µg/mL) 
(Abcam Ab156769, Cambridge MA, USA) and CD68 (1 µg/mL) (Fisher Scientific 
Thermo MS-397, Pittsburg, PA, USA); for T cells, an antibody for CD3 (1ug/mL) 
(Abcam Ab699, Cambridge, MA, USA). To detect proliferative cells, we labeled 
with an antibody against Ki-67 (5 µg/mL) (Abcam Ab15580, Cambridge, MA, USA) 
and ProLong Gold® anti-fade medium with DAPI nuclear stain (Life Technologies 
#P36931, Carlsbad, CA, USA). For all labels, we used Tris buffer (pH 9.0) for 
epitope recovery, except for Ki-67 where we used citrate buffer (pH 6.0). Isotype 
control slides were stained with rabbit IgG (Vector Laboratories #I-1000, 
Burlingame, CA, USA) or mouse IgG1 (eBioscience #14-4714-85, San Diego, CA, 
USA), IgG2a (eBioscience #14-4724-85, San Diego, CA, USA), or IgG2b 
(eBioscience #14-4732-85, San Diego, CA, USA) at the same concentration as 
their respective primary antibodies. Primary antibodies to TGF-β1 and Ki-67 were 
labeled with a goat anti-rabbit IgG secondary antibody coupled with Alexa Fluor® 
555 (Life Technologies #A21429, Carlsbad, CA, USA) and all other primary 
antibodies were labeled with a goat anti-mouse IgG secondary antibody coupled 
with Alexa Fluor® 647 (Life Technologies #A21236, Carlsbad, CA, USA). All 
labeling procedures were performed with a fully programmable, robotic autostainer 
(BioGenex i6000 Model, Fremont, CA, USA). 
Detection of Fibroblast Accumulation by Immunohistochemistry 
Duplicate slide specimens were deparaffinized and heated in Tris buffer (pH 
9.0) for epitope recovery. Specimens were blocked with 10% goat serum for 5 
minutes, treated with primary antibody against TE-7 (1:10 dilution) (Millipore 
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CBL271, Billerica, MA, USA), a highly specific marker of fibroblasts172-174, and 
incubated for 14 hours. An isotype control treated with the same concentration of 
mouse IgG1 (EBioscience #14-4714-85, San Diego, CA, USA) was included with 
each duplicate antibody-treated pair of slide. Specimens were treated with 
peroxidase-conjugated secondary antibody according to instructions from DAB 
Polink 2 Kit (GBI Labs #D22-60D, Bothell, WA, USA). Hematoxylin (Fisher 
Scientific Richard Allan Scientific #72511, Pittsburg, PA, USA) was used as the 
counterstain for 4 minutes. Slides were dehydrated and mounted in Permount 
(Fisher Scientific #SP15-100, Pittsburg, PA, USA). Staining was implemented with 
a fully programmable, robotic autostainer (BioGenex i6000 Model, Fremont, CA, 
USA). 
Statistical Analyses 
The baseline characteristics between PAD and controls subjects were 
compared using general linear models for continuous variables and chi-square test 
for categorical variables to determine confounders. Confounding variables were 
covariates in subsequent analyses. For all biological parameters, group 
differences were determined by analysis of covariance (ANCOVA) and evaluated 
post-hoc by Bonferroni adjusted t-tests. Correlations were assessed by the 
Pearson test. All data are expressed as mean ± SD. All statistical analyses were 
performed with SPSS 20 (IBM, Armonk, NY, USA) using a confidence level of 95%.  
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Results 
PAD Gastrocnemius Exhibits Increased Collagen Deposition with Advancing 
Disease 
Spectral imaging revealed increased collagen density with higher Fontaine 
stage, which became diffuse in Stage IV muscle (Figure 2.5A). Collagen density 
and area in PAD muscle was increased between the myofibers and around the 
lumen of microvessels. The most noticeable pathological change was dense 
collagenous investment of the microvessels of PAD muscle (arrows). Spectral 
analysis established increased collagen density (p < 0.001) and area (p < 0.001) 
at the higher Fontaine stage. Collagen density in the PAD-IV patients (2708.8 ± 
612.3 gsu) was 40% and 75% greater than in PAD-II and CTRL patients, 
respectively (1969.9 ± 277.5 gsu and 1551.7 ± 232.8 gsu; both p < 0.001), while 
collagen density was 25% greater in PAD-II compared to CTRL (p = 0.015; Figure 
2.5B). Collagen area was approximately twice as great in PAD-IV (241179 ± 
133159 mm2) compared to either PAD-II or CTRL gastrocnemius (109179 ± 56481 
mm2 and 118624 ± 99559 mm2; both p < 0.01), with no difference between PAD-
II and CTRL (Figure 2.5C). These data suggest that increased collagen deposition 
occurs first around microvessels and then expands throughout the extracellular 
matrix between myofibers and myofascicles as PAD advances.  
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Figure 2.5: Collagen Deposition in the Gastrocnemius of CTRL and PAD 
Patients with Claudication and Tissue Loss157. (A) Representative gray scale 
images of gastrocnemius specimens stained with Masson Trichrome were 
captured by multi-spectral, bright-field microscopy at 20x objective. Specimens 
were collected from control (CTRL) and Fontaine Stage-II and Fontaine Stage-IV 
PAD patients (PAD-II and PAD-IV respectively). Myofibers delineated by collagen 
staining appear black. Collagen density and area are represented by the intensity 
and extent of the bright pixels, respectively. Arrows point to collagen deposition 
associated with microvessels. (B) Collagen density and (C) collagen area in 
specimens of CTRL (n=20), PAD-II (n=25), and PAD-IV (n=20) gastrocnemius 
were analyzed by quantitative multi-spectral microscopy. Collagen density was 
calculated as area-weighted mean intensity of all collagen events per specimen. 
Data are presented as mean ± SEM. Significance is denoted as * p < 0.05, ** p < 
0.01, and *** p < 0.001. 
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TGF-β1 Expression is Tightly Linked to Myofibrosis of PAD Gastrocnemius 
QFM imaging localized TGF-β1 expression to the vasculature of both CTRL 
and PAD muscle, with no detectable labeling outside of the vascular walls (Figure 
2.6A). TGF-β1 expression was uniformly low in CTRL muscle and exhibited a 
progressive increase in PAD-II and PAD-IV muscle. PAD-IV gastrocnemius had 
approximately 2.5 and 8 fold greater expression of TGF-β1 compared to PAD-II 
and CTRL patients (6.56 ± 3.12 gsu vs. 2.89 ± 2.12 gsu and 0.842 ± 0.399 gsu, 
respectively; both p < 0.001), while PAD-II had 3.5 fold more TGF-β1 than CTRL 
(p < 0.05; Figure 2.6B). Vascular TGF-β1 expression positively correlated with 
collagen density across all subjects (N=65) in this study (r = 0.798, p < 0.001; 
Figure 2.6C). Separate analysis of the PAD patients alone (PAD-II and PAD-IV; 
N=45) and the CTRL subjects alone (N=20) revealed a significant correlation 
between TGF-β1 and collagen density in PAD group (r = 0.854, p < 0.001), but not 
in the CTRL group (r = 0.119, p = 0.618), indicating that the pathological fibrosis 
in PAD is driven by TGF-β1 expression. These findings identify increased 
microvascular TGF-β1 expression as a characteristic of PAD muscle and establish 
an association between increased TGF-β1 expression and muscle fibrosis and 
between increased TGF-β1 expression and advancing disease stage. 
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Figure 2.6: TGF-β1 Expression in CTRL and PAD Gastrocnemius and its 
Relationship with Collagen Density and ABI157. (A) Representative gray scale 
images of gastrocnemius microvessels positive for TGF-β1 labeling (arrows) were 
captured with a wide-field fluorescence microscope (10x objective). Unlabeled 
myofibers (blue line) appear grey against black background. Specimens collected 
from Control (CTRL) and Fontaine Stage-II and Fontaine Stage-IV PAD patients 
(PAD-II and PAD-IV respectively) were labeled with primary antibody specific for 
TGF-β1 and a fluorescent secondary antibody. Both the intensity and extent of 
TGF-β1 labeling were increased in the microvessels of PAD vs. CTRL and PAD-
IV vs. PAD-II specimens. (B) TGF-β1 expression was determined by Quantitative 
Fluorescence Microscopy and defined as the sum of the products of area and 
mean pixel intensity of all positive events per microscopic field, normalized to the 
total area of specimen in the same field. (C) The relationships between TGF-β1 
expression and collagen density. Data are presented as mean ± SEM. Significance 
is denoted as * p < 0.05, ** p < 0.01, and *** p < 0.001. 
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Hemodynamics Predicts TGF-β1 Associated Myofibrosis in PAD Limbs 
Across all subjects (N=65) in this study, vascular TGF-β1 expression 
increased with decreasing ABI (r = -0.694, p < 0.001; Figure 2.7A), which is an 
indicator of blood flow (hemodynamic) compromise and increased ischemia of the 
lower limbs. The relationship between TGF-β1 and ABI remained significant when 
analyzing PAD patients alone (r = -0.543, p < 0.001). Similarly, collagen density 
increased with decreasing ABI across all patients (r = -0.734, p < 0.001; Figure 
2.7B) and the relationship remained significant when analyzing PAD patients alone 
(r = -0.632, p < 0.001). These findings show that as the blood flow (and presumably 
oxygenation) to the leg is decreased by atherosclerotic blockages in the arteries 
supplying the legs (reflected by decreasing ABI) there is a corresponding increase 
in the expression of TGF-β1 expression in the microvessels and collagen 
deposition in the muscles of the affected leg.  
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Figure 2.7. Hemodynamics Predicts TGF-β1 Associated Myofibrosis in PAD 
Limbs157. (A) Pearson correlation between Ankle-Brachial Index and TGF-β1 
expression across all patients. (B) Pearson correlation between Ankle-Brachial 
Index and collagen density across all patients. The threshold for significance was 
p < 0.05. 
A 
B 
r = -0.734            
p < 0.001  
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Increased Expression of TGF-β1 is Associated with Accumulation of 
Fibroblasts and Collagen Deposition in PAD Gastrocnemius  
To further evaluate the concept of a TGF-β1 associated myofibrosis in PAD, 
we selected three adjacent gastrocnemius sections and stained the first section 
for collagen with Masson Trichrome, the second for TE-7 positive fibroblasts by 
immunohistochemistry, and the third for TGF-β1 by immunofluorescence. Images 
from a PAD-IV patient with significant fibrosis are shown in Figure 2.8. In areas of 
dense collagen deposition (ellipse, Figure 2.8A), we observed a high density of 
fibroblasts (ellipse, Figure 2.8B). This is in contrast to areas containing relatively 
little collagen (circle, Figure 2.8A), which had very few fibroblasts (circle, Figure 
2.8B). Vessels near the heavily fibrotic areas (high magnification of the square 
in Figure 2.8) contain a high density of fibroblasts (Figure 2.8C) in association 
with intense TGF-β1 labeling (Figure 2.8D) and dense adventitial collagen 
(square, Figure 2.8A). These observations are consistent with the pro-fibrotic 
activity of TGF-β1, where TGF-β1 activates motile fibroblasts that deposit 
collagen73,74, and establish a spatial association of increased TGF-β1 expression, 
fibroblast accumulation, and collagen deposition as a characteristic of PAD 
pathophysiology. They also further demonstrate that the microvessels of ischemic 
legs play a key role in the pathophysiology of PAD myofibrosis. 
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Figure 2.8: Association of TGF-β1 Expression with Fibroblast Accumulation 
and Collagen Deposition in Gastrocnemius of PAD Patients157. All images 
are of gastrocnemius of a representative Fontaine Stage-IV PAD patient. (A) 
Masson Trichrome staining reveals highly fibrotic regions (blue labeling) around 
myofibers (oval) and microvessels (rectangle), and a region with relatively little 
fibrosis (circle). (B) A neighboring 4-micron section was labeled by 
immunohistochemistry with anti-TE-7 antibody, a fibroblast marker which 
identified fibroblasts in the same three regions of interest. (C) High magnification 
of the rectangular region of interest reveals the extent of fibroblast accumulation 
with microvessels. (D) A neighboring section labeled by immunofluorescence for 
TGF-β1 (green fluorescence) shows the intensity and extent of TGF-β1 labeling 
of microvessels within the rectangular region of interest. Wheat Germ Agglutinin 
(WGA; red fluorescence) labeled membranes and was used to delineate 
myofibers.  
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Vascular Smooth Muscle Cells are the Producers of TGF-β1 in the 
Microvessels of PAD Gastrocnemius 
To determine the specific cellular source of TGF-β1 expression in the 
microvessels of PAD gastrocnemius, we implemented co-localization studies with 
antibodies for highly specific markers of candidate vascular cells, including 
endothelial cells, SMC, fibroblasts, macrophages, and T cells (Figure 2.9). TGF-
β1 labeling did not co-localize with CD163 positive macrophages (Figure 2.9A), 
CD3 positive T cells (Figure 2.9B), or CD31 positive endothelia (Figure 2.9C). TE-
7 positive fibroblasts located in the adventitia were not positive for TGF-β1, nor 
were cells stained with TE-7 in the intima, which may represent endothelial-
mesenchymal transition (Figure 2.9D). TGF-β1 co-localized with cells expressing 
high molecular weight caldesmon, a marker of SMC that is not found in 
macrophages or fibroblasts175,176 (Figure 2.9E). Prominent co-localization was 
observed in rhomboidal-shaped SMC located in the subendothelial region 
(arrows). This has been reported for other vascular fibrotic pathologies, where 
SMC are activated toward the pro-fibrotic synthetic phenotype, including in 
atherosclerotic arterial plaques. Many of the rhomboidal SMC stained positive for 
Ki-67 in the nuclei (arrowheads; Figure 2.9F), indicating they are proliferative and 
activated. The finding that TGF-β1 is derived from locally proliferative SMC rather 
than immune cells in PAD myofibrosis is novel.  
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Figure 2.9: Evaluation of Candidate 
Vascular Cells for Expression of 
TGF-β1157. All immunofluorescence 
images are from PAD patients who 
present with tissue loss and are 
representative of all diseased patients in 
our study. (A) TGF-β1 labeling (green) 
does not co-localize with CD163 
positive macrophages (red) present at 
relatively high density in the adventitia 
of microvessels. High magnification of 
the boxed region reveals cellular labeling of CD163 around DAPI stained nuclei 
(blue). (B) TGF-β1 labeling (green) does not co-localize with CD3 positive T cells 
(red) that are located typically around myofibers near microvessels. High 
magnification of the boxed region reveals cellular labeling of CD3 around DAPI 
stained nuclei (blue). (C) TGF-β1 labeling (green) does not co-localize with CD31 
positive endothelial cells (red) that are characteristically located in the intima of 
microvessels. (D) TGF-β1 labeling (green) does not co-localize with TE-7 positive 
fibroblasts (red). (E) TGF-β1 labeling (green) co-localizes with high molecular 
weight caldesmon (h-Caldesmon) a specific marker of smooth muscle cells (red). 
Arrows point to rhomboidal morphology characteristic of secretory SMC. (F) The 
proliferation marker Ki-67 (green) is expressed in nuclei (blue) of h-Caldesmon 
positive SMC (red) that highly express TGF-β1 as determined with a neighboring 
tissue section. 
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Discussion 
This study established that vascular TGF-β1 is strongly associated with 
myofibrosis during the progression of PAD. Using rigorous quantitative methods, 
we have shown that vascular expression of TGF-β1 and collagen deposition in 
PAD gastrocnemius increased in parallel with advancing disease severity. 
Qualitatively, TGF-β1 production was limited to cells in the walls of the 
microvessels in affected PAD muscle. In advanced disease, these cells expressing 
TGF-β1 were present at high density and were associated with accumulation of 
fibroblasts and increased deposition of collagen around the vessels and 
throughout an expanded interstitium. Our findings suggest that increased vascular 
TGF-β1 induces PAD myofibrosis by activating fibroblasts that proliferate and 
either stay locally around the microvessels or migrate between myofibers and 
around myofascicles into areas of myofiber degeneration, thus being responsible 
for the perivascular and endomysial/perimysial fibrosis we and others177,178, have 
shown in the affected leg muscles of PAD patients. Accumulation of fibrous tissue 
in the PAD muscle can affect the muscle both by compromising the function of its 
myofibers and myofascicles but also by interfering with the function of its 
microvessels. The fibrosis of microvessels in PAD muscle has been shown by us 
and others177,178 to involve both collagenous thickening of the capillaries and 
muscularization and fibrosis of normally non-muscularized microvessels and is 
known to impair diffusion of gases and small molecules between the vasculature 
and end organ parenchyma, probably enhancing the tissue hypoxia and inducing 
myofiber degeneration in the affected PAD legs. TGF-β1 may also be contributing 
91 
 
to PAD myopathy by suppressing skeletal muscle regeneration by inducing 
myoblasts to differentiate into myofibroblasts rather than new myofibers158,159. This 
model of PAD myofibrosis is consistent with the contribution of TGF-β1 to fibrosis 
and muscle degeneration seen in other skeletal myopathies71 and 
myocardiopathies179,180.  
Another novel finding of this study is that TGF-β1 is expressed exclusively 
by vascular SMC in PAD muscle. Our co-localization studies show conclusively 
that TGF-β1 is produced by vascular SMC and not in the associated fibroblasts, 
suggesting that these fibroblasts are activated by TGF-β1 produced in the SMC. 
These observations again point to a widely reported mechanism of fibrosis in 
human fibrotic diseases, in which TGF-β1 activates fibroblasts to myofibroblasts. 
Our co-localization studies also revealed that macrophages and T cells, which are 
reported to be the source of TGF-β1 in other skeletal myofibroses, did not express 
detectable TGF-β1 in PAD muscle70,71. This is likely due to the different etiology of 
PAD myofibrosis compared to other skeletal myopathies, of which the muscular 
dystrophies are the best studied. The primary cause of PAD myopathy is 
atherosclerotic stenoses and occlusions of large arteries that supply the legs, 
which produce ischemia and hypoxia in the lower extremities181. Over time, chronic 
hypoxia may damage the muscle myofibers to produce their characteristic 
degeneration and induce SMC of the microvessels to increase TGF-β1 expression 
and cause myofibrosis. In contrast, muscular dystrophies originate from mutated 
genes that code for defective skeletal muscle proteins primarily involved in 
transmitting sarcomeric forces to the extracellular matrix70,71. In muscular 
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dystrophies, repeated cycles of myofiber degeneration and regeneration induce a 
chronic inflammatory response that includes TGF-β1 production by activated 
immune cells and produces the myofibrosis. Progressive fibrosis in PAD muscle 
appears not to be a response to chronic inflammation. We have profiled cytokines 
in the gastrocnemius of moderately diseased PAD patients and, indeed, did not 
find a generalized inflammatory signature157. The unique cytokine milieu produced 
by chronic ischemia in PAD gastrocnemius may explain why we did not observe 
detectable TGF-β1 in macrophages and T cells as is seen, e.g., in muscular 
dystrophies. Overall, the vascular etiology of PAD myofibrosis points to the 
possibility that chronic hypoxia of microvessels causes increased expression of 
TGF-β1 by SMC. 
In PAD, hypoxic injury may cause transitioning of SMC from a contractile to 
a synthetic phenotype that is pro-fibrotic. Vascular SMC are normally contractile, 
with a spindle-shaped morphology and an abundance of contractile proteins that 
allow them to regulate vessel diameter. Under various pathological conditions 
marked by hypoxia, SMC can acquire a synthetic phenotype marked by 
rhomboidal morphology, decreased contractile proteins, and the ability to 
proliferate, migrate, and deposit collagen76,77. In this study, we found that patients 
with lower ABI had greater expression of TGF-β1 across Fontaine Stages of 
disease, which suggests that hypoxia induces SMC to increase TGF-β1 
expression. This is supported by our observation that many SMC with increased 
TGF-β1 expression were proliferative and exhibited a rhomboidal morphology that 
is characteristic of synthetic SMC.  
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The responses of vascular SMC to hypoxia, in pulmonary arterial 
hypertension (PAH), are likely similar to those in the ischemic muscle of PAD 
patients and may provide insight into the mechanisms by which TGF-β1 
expression is increased in PAD muscle. PAH is a condition characterized by 
substantial thickening of the vascular wall caused by extensive proliferation of 
SMC that exhibit increased TGF-β1 expression and deposition of collagen164,165. 
Hypoxia alone can stimulate proliferation of human pulmonary SMC in culture164. 
Alternatively, growth factors released by cultured endothelial cells exposed to 
hypoxia also can stimulate proliferation of SMC182. Either or both mechanisms may 
operate in vivo causing SMC to shift towards a more proliferative, synthetic 
phenotype in PAH. In PAD gastrocnemius, SMC with intense TGF-β1 labeling 
were observed frequently in the sub-endothelial region, suggesting that hypoxic 
insult to endothelial cells may stimulate secretion of growth factors that cause SMC 
to increase TGF-β1 expression. Given the histopathological similarities between 
PAH and PAD, future mechanistic studies of PAD myofibrosis should determine 
whether chronic hypoxia directly induces TGF-β1 expression by SMC, and/or 
activates endothelial cells to increase production of pro-fibrotic factors that cause 
SMC to increase expression of TGF-β1.  
Understanding the mechanism by which chronic hypoxia stimulates SMC 
production of TGF-β1 can lead to development of animal models that recapitulate 
the myofibrosis observed in patients with PAD. Such models will allow for testing 
of novel anti-fibrotic therapies that modulate the cellular phenotypes and growth 
factors released from specific cell types to reduce SMC expression of TGF-β1 and 
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myofibrosis. Importantly, we can determine side effects in these animals that may 
hamper the success of therapeutic strategies. Additionally, limb function can be 
assessed over time and in relation to changes in myofibrosis. 
A limitation of this study is the number of human subjects, however our 
power calculations indicated enough statistical power to analyze each of the 
biological parameters. The main barriers against recruitment of additional human 
subjects are the rigorous inclusion and exclusion criteria used to reduce 
confounding variables, and the demands of obtaining muscle biopsies. PAD 
patients included in our study must have had exercise-limiting claudication 
established by history and direct observation during a screening walk test 
administered by a vascular surgeon. We enrolled only those patients who did not 
exhibit concurrent symptoms of heart, lung, musculoskeletal (mainly arthritis), and 
neurologic (mainly back pain and sciatica) ailments that would affect their walking 
ability and their performance in the screening walk test. Furthermore, we excluded 
individuals with 1) asymptomatic PAD, i.e. patients with occlusive arterial disease 
who do not have claudication symptoms or tissue loss/gangrene, 2) acute lower 
extremity ischemic events secondary to thromboembolic disease or acute trauma, 
and 3) exercise capacity limited by conditions other than claudication including leg 
(joint or musculoskeletal and neurologic) and systemic (heart and lung disease) 
pathology. The invasiveness of a muscle biopsy and the time required often 
discourages participation of PAD patients and control subjects especially when the 
muscle biopsy cannot be performed during their routine care (at the time of a leg 
operation) which was frequently the case for most PAD-II and control patients. With 
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the 65 patients recruited, post-hoc power sample analysis using the data (mean 
and SD) for collagen density and area, and TGF-β1 expression, revealed adequate 
statistical power. Power sample analysis for an ANCOVA of TGF-β1 expression 
demonstrated that a total sample size of N=65 (20, 25 and 20 subjects per group) 
assured at least 99% power to detect differences between groups adjusting for two 
covariates with a conservative R2 value of 0.20. Similarly, for an ANCOVA of 
collagen density and area, our sample size assured at least 99% and 93% power, 
respectively, to detect differences between the groups adjusting for two covariates 
with a conservative R2 value of 0.20. The power and sample size determination 
package PASS (PASS, Number Cruncher Statistical Systems, Kaysville, UT) was 
used for the analysis.  
An additional limitation is the correlational nature of the study, but the high 
quality human data that we have presented for PAD myofibrosis provide a basis 
for future mechanistic studies, development of disease models, and improved 
therapies and prognosis. In this study, we established an association between 
ischemia and increased TGF-β1 production by microvascular SMC. We have 
identified microvascular SMC in PAD muscle as the exclusive producer of TGF-
β1, making it a specific target for anti-fibrotic therapies for PAD. Candidate 
therapeutic drugs will be those capable of shifting the pro-fibrotic synthetic 
phenotype of SMC back to the contractile form to decrease TGF-β1 expression 
and prevent or slow down the progression of PAD myofibrosis. Moreover, TGF-β1 
production by SMC may be a potential biomarker for determining efficacy of 
therapeutics, including anti-fibrotic interventions. Finally, our finding of worsened 
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myofibrosis with advancing Fontaine Stage in PAD suggests that the patients who 
are optimal for anti-fibrotic intervention are those with moderate disease, since 1) 
a relatively small proportion of vascular SMC express TGF-β1, 2) fibroblasts are 
present at relatively low density, and 3) collagen deposition is largely limited to 
microvessels with little expansion into the interstitium. 
Fibrosis is often viewed as an adaptive response to injury and tissue 
degeneration, but as we have shown in this study, can be part of the 
pathophysiology of chronic disease. We have established that increased 
expression of TGF-β1 by microvascular SMC in the gastrocnemius of PAD patients 
correlates with Fontaine Stage and increasing collagen deposition. The pattern of 
vascular TGF-β1 expression, fibroblast accumulation, and collagen deposition 
points to pathological changes in microvessels as the immediate cause of PAD 
myofibrosis. The contribution of hypoxia was suggested by a strong negative 
correlation between ABI and vascular TGF-β1 expression and presence of locally 
proliferative rhomboidal SMC in microvessels of PAD gastrocnemius that are 
indicative of the pro-fibrotic synthetic phenotype of SMC known to be induced by 
hypoxia. Collectively, these findings provide insight into the development of PAD 
myofibrosis and direction for future mechanistic studies, and consequently, basis 
for improved diagnosis and treatment for PAD patients.  
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CHAPTER III: TGF-β1 ASSOCIATED MYOFIBROSIS IS A LOCALIZED 
RESPONSE IN THE ISCHEMIC MUSCLE OF PAD PATIENTS 
  
Introduction 
            The work presented in Chapter II established myofibrosis as part of the 
myopathy of PAD, but whether or not it arises predominantly as a local response 
to ischemia or also as a consequence of systemic changes could not be 
determined. This is because studies of PAD patients with bilateral disease mask 
the contributions of systemic factors to local myopathy. In the context of 
myofibrosis, it is conceivable that pathological factors in circulation, either directly 
related to atherosclerosis or not, induced the expression of TGF-β1 expression by 
vascular SMC and associated increase in collagen deposition56. It is important to 
determine if systemic contributions exist because this knowledge will allow for the 
development of appropriate strategies that decrease TGF-β1 expression in 
microvessels to reverse or prevent myofibrosis in PAD patients. For example, if 
systemic contributions do exist, focusing solely on relieving ischemia may not alter 
TGF-β1 expression and lead to novel therapeutic targets in circulation being 
overlooked. Determination of systemic contributions to other aspects of myopathy 
have been achieved by studies of PAD patients with unilateral disease, in which 
significant atherosclerosis and decrease in ABI is present in only one of the limbs. 
In unilateral PAD patients, presence of myopathy in only the hemodynamically 
comprised limb would indicate that the myopathy is a direct consequence of 
atherosclerosis in that limb, with minimal systemic contributions.   
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Previous studies of the abnormal bioenergetics in the gastrocnemius of 
unilateral PAD patients revealed systemic contributions and further demonstrate 
the need for these studies for myofibrosis. Metabolic changes in PAD skeletal 
muscle have been defined with features similar to those of mitochondrial 
myopathies48,183,184. In unilateral disease PAD patients, mitochondrial DNA 
deletions are increased in both the affected and contralateral limb compared to 
controls, but are not significantly different from each other185,186. This suggests that 
mitochondrial injury may not have a primary role in the pathogenesis of PAD 
myopathy. Furthermore, there was a significant correlation between the degree of 
mitochondrial deletion in the affected and contralateral limbs185,186 which indicates 
that the contralateral limb reflects a subclinical phenotype of the ischemic limb. 
Similarly, in a separate study of unilateral disease PAD patients, skeletal muscle 
carnitine metabolism was shown to exhibit a similar pattern49. Taken together, 
these findings suggest that abnormal bioenergetics in the skeletal muscle of PAD 
may not be a direct consequence of atherosclerosis and the local ischemia 
produced in that limb, since abnormalities lateralized between the limbs. Given that 
atherosclerosis is a systemic disease associated with oxidative stress187-189, 
biological factors such as free radicals in the circulation may be responsible for the 
impaired bioenergetics in both limbs, especially since the same types of 
mitochondrial deletions in skeletal muscle were also found in atherosclerotic 
lesions190. However, the opposite interpretation may have been made had only the 
limbs of bilateral PAD patients been studied. Thus, it is imperative that unilateral 
PAD patients are studied to determine if systemic contributions contribute to 
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myofibrosis or if it is a response to local ischemia produced by atherosclerosis in 
that specific limb. 
In Chapter II, TGF-β1 expression was inversely correlated with ABI 
measurements, indicating that the decreased blood flow, and consequent 
ischemia-hypoxia may be stimulating SMC to increase production of TGF-β1. 
Preliminary data in our laboratory demonstrates a cytokine profile in the muscle 
that is different from serum in PAD patients, with TGF-β1 being significantly higher 
in muscle than serum (Chapter I, Table 1.2). This suggests that the fibrotic effects 
of TGF-β1 may arise from local ischemia-reperfusion injury. Studies of neutrophils, 
one of the major producers of cytokines that can circulate into end organs, found 
that in unilateral disease PAD patients, number of neutrophils and percentage 
activated was higher in venous than arterial blood65. Moreover, compared to the 
diseased limb, this difference was not found in the contralateral limb, further 
suggesting a unique local cytokine response. These findings provide rationale for 
the following study that addresses Specific Aim 2.  
To test the hypothesis that TGF-β1 expression and the subsequent collagen 
deposition is a localized response in the ischemic muscle of PAD patients, we 
compared myofibrosis between the limbs of PAD patients with unilateral disease 
and explored correlative relationships between the limbs for TGF-β1 expression 
and collagen density. If myofibrosis is a localized response, then the diseased limb 
will have significantly greater TGF-β1 expression and collagen density compared 
to the contralateral limb, with no correlation between the limbs in either 
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measurement. However, if systemic contributions exist, then TGF-β1 expression 
and collagen density will be similar between the limbs with a direct relationship 
between the limbs in both measurements.  
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Methods 
Characteristics of Human Subjects 
We studied a total of 10 Fontaine Stage-II PAD patients with unilateral 
disease, where only one of the two limbs has atherosclerosis significant enough to 
produce claudication. The diagnosis for each PAD patients was established on the 
basis of medical history, physical examination, decreased ankle-brachial index 
(ABI < 0.9), and computerized or standard arteriography that revealed stenotic 
and/or occluded arteries supplying the lower limbs. ABI was measured by first 
taking blood pressure measurements from both brachial arteries and from both the 
dorsalis pedis and posterior tibial arteries after patients have been at rest in the 
supine position for 10 minutes. The ratio is calculated by taking the averaged ankle 
blood pressures and dividing by the averaged blood pressures obtained from the 
arm. Using ABI measurements, we confirmed that the diseased leg had 
significantly lower ABI than the contralateral leg (mean ± SD; 0.49 ± 0.21 vs. 0.99 
± .10, respectively; p = 0.005). All of the diseased legs had ABI < 0.9, while only 
one of the contralateral legs had an ABI < 0.9, demonstrating that these patients 
are suitable for this study. We did not examine demographics such as co-
morbidities as potential confounders since each patient served as his or her own 
control. The experimental protocol was approved by Institutional Review Boards 
from the Veterans Affairs Nebraska-Western Iowa and University of Nebraska 
Medical Centers, and all patients gave informed consent. 
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Quantitative Assessment of Collagen Density 
Multi-spectral imaging analysis measured the density of collagen in both the 
diseased and contralateral limbs as previously described in Chapter II Methods. 
Quantitative Assessment of TGF-β1 Expression 
Quantitative fluorescence microscopy measured the expression of TGF-β1 
expression in both the diseased and contralateral limbs as previously described in 
Chapter II Methods. Quantitative PCR was performed on both the diseased and 
contralateral limbs and normalized to Myosin Heavy Chain transcript levels as 
described in Chapter II Methods. 
Statistical Analysis 
All data are expressed as mean ± SEM. Comparison of ABI between the 
groups was performed using the non-parametric Wilcoxon Rank-Signed Test. 
Similarly, TGF-β1 expression and collagen density were analyzed by the Wilcoxon 
Rank-Signed Test. All correlational analyses were performed using the non-
parametric Spearman test. All statistical analyses were performed with SPSS 20 
(IBM, Armonk, NY, USA) using a confidence level of 95%. 
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Results 
TGF-β1 Expression is Independently Greater in the Diseased Compared to 
Contralateral Leg of PAD Patients with Unilateral Disease 
            Compared to the contralateral limb, labeling of TGF-β1 appeared brighter 
in microvessels of all sizes, both those located in the perimysial and endomysial 
regions of PAD gastrocnemius (Figure 3.1A). QFM measured a greater than 4-
fold expression of TGF-β1 in the diseased compared to contralateral limb (mean 
± SEM; 3.27 gsu ± 0.74 vs. 0.76 gsu ± 0.20 respectively; p = 0.013; Figure 
3.1B). Correlational analysis revealed no relationship between the diseased and 
contralateral limbs for TGF-β1 expression (r = 0.181; p = 0.543).  
            Quantitative PCR measured changes in TGF-β1 expression at the 
transcript level between the limbs and results were similar to QFM measurements 
of TGF-β1 expression at the protein level. Compared to the contralateral limb, 
there was an approximately 7.5-fold greater expression of TGF-β1 transcripts, 
normalized to myosin heavy chain, in the diseased limb (0.00465 ± 0.00095 vs. 
0.00061 ± 0.00016; p = 0.007; Figure 3.1C). Correlational analysis revealed no 
relationship between the diseased and contralateral limbs for mRNA levels of TGF-
β1 (r = 0.006; p = 0.987). Correlational analysis was also performed between 
protein and transcript TGF-β1 levels across all limbs. A direct relationship 
demonstrates that QFM and qPCR cross-validated one another (r = 0.720; p < 
0.001; Figure 3.1D). 
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Figure 3.1: TGF-β1 Expression is Independently Greater in the Diseased 
Compared to Contralateral Leg of PAD Patients with Unilateral Disease. (A) 
Representative gray scale images of gastrocnemius microvessels positive for 
TGF-β1 labeling were captured with a wide-field fluorescence microscope (10x 
objective). Higher magnification images were taken (20x objective) to highlight 
differences present in microvessels located between myofibers. Specimens 
collected from both legs of PAD patients at Fontaine Stage II with unilateral 
disease. (B) Quantitative Fluorescence Microscopy measured the expression of 
TGF-β1 expression in both limbs. (C) Quantitative PCR measured transcript levels 
in the gastrocnemius of both limbs, normalized to myosin heavy chain transcripts. 
(D) Spearman correlation between QFM and qPCR measurements of TGF-β1. 
Data are presented as mean ± SEM and significance threshold is p < 0.05. 
D 
A B 
C 
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Collagen Density is Independently Greater in the Diseased Compared to 
Contralateral Leg of PAD Patients with Unilateral Disease 
Compared to the contralateral limb, the labeling of collagen appeared 
brighter in the gastrocnemius of PAD patients (Figure 3.2A). Quantitative muti-
spectral microscopy measured a 25% increase in the density of collagen in the 
diseased compared to contralateral limb (mean ± SEM; 2162 gsu ± 99 vs. 1739 
gsu ± 73 respectively; p = 0.013; Figure 3.2B). Correlational analysis did not 
reveal a significant relationship between the diseased and contralateral limbs for 
TGF-β1 expression (r = 0.254; p = 0.368).  
Relationship between TGF-β1 Expression and Collagen Density in the 
Limbs of PAD Patients with Unilateral Disease 
Correlational analysis revealed a significant relationship between vascular 
TGF-β1 expression and collagen density in the diseased limbs (r = 0.69; p = 
0.03; Figure 3.3A), but such a relationship did not exist in the contralateral limbs 
of PAD patients (r = 0.42; p = 0.23; Figure 3.3B). 
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Figure 3.2: Collagen Density is Independently Greater in the Diseased 
Compared to Contralateral Leg of PAD Patients with Unilateral Disease. (A) 
Representative gray scale images of gastrocnemius specimens stained with 
Masson Trichrome were captured by multi-spectral, bright-field microscopy (20x 
objective). Specimens were collected from both legs of PAD patients at Fontaine 
Stage II with unilateral disease. Myofibers delineated by collagen staining, appear 
black. Collagen density and area are represented by the intensity and extent of the 
bright pixels, respectively. (B) Collagen density was measured by quantitative 
multi-spectral microscopy as area-weighted mean intensity of all collagen events 
per specimen. Data are presented as mean ± SEM and the significance threshold 
is p < 0.05. 
A 
B 
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Figure 3.3: Relationship between TGF-β1 Expression and Collagen Density 
in the Limbs of PAD Patients with Unilateral Disease. (A) Spearman correlation 
in diseased limbs. (B) Spearman correlation in contralateral limbs. A threshold of 
p < 0.05 was considered significant.  
 
 
r = 0.685 
p = 0.029   
A 
r = 0.415 
p = 0.228 
B 
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Discussion 
            Examination of myofibrosis in the limbs of unilateral disease PAD patients 
revealed that it is a localized response in ischemic muscle without significant 
systemic contribution. The greater vascular TGF-β1 expression and collagen 
density in the diseased compared to contralateral limb indicates that the presence 
of significant atherosclerosis and ischemia is the predominant driver of 
myofibrosis. This is further corroborated by correlational analyses that showed no 
relationship of either TGF-β1 expression or collagen density between the limbs. 
Lack of a relationship between myofibrosis in the limbs makes it highly unlikely that 
a pathological factor from the diseased limb circulates and induces myofibrosis in 
the contralateral limb. Such a pattern is different from previous studies of 
bioenergetic abnormalities in PAD skeletal muscle, where lateralization between 
the limbs did occur, reflected in the correlation of mitochondrial deletions between 
the limbs185,186. A direct relationship between TGF-β1 expression and collagen 
density was also detected in the diseased but not contralateral limb, further 
demonstrating that the presence of significant atherosclerosis is needed for the 
development of TGF-β1 associated myofibrosis. With aging, vascular TGF-β1 
expression is known to increase105, which may account for vascular TGF-β1 in the 
contralateral limb and thus, it is logical that those levels are not accompanied by 
increased collagen density in the gastrocnemius. Overall, myofibrosis is a local 
myopathy that develops and is not a consequence of systemic pathological 
changes. Thus, therapeutic strategies that alleviate ischemia-hypoxia and reduce 
TFG-β1 expression will likely have direct improvements in the myopathy of PAD. 
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            These findings also have important implications regarding improvement of 
limb function, since biomechanical studies in PAD patients with unilateral disease 
demonstrate that both limbs are dysfunctional. Comparison of joint torques and 
powers in both limbs of unilateral disease PAD patients while walking showed 
significant gait impairments in both limbs that are present before the onset of 
ischemic pain191. Moreover, the dysfunction of the contralateral limb is significantly 
greater than in the limbs of age matched controls191. In a separate study, energy 
output in the diseased and contralateral limbs at rest showed that both legs 
performed less work than healthy controls and were not significantly different from 
each other192. Perhaps this is a functional sequelae of the bioenergetics 
abnormalities in the PAD muscle that are associated with both local ischemia and 
systemic factors. If so, treatments that do not address both aspects, may not yield 
benefits to limb function. In contrast, targeting TFG-β1 expression locally will likely 
produce direct benefits to limb function, since there is not a significant systemic 
contribution. An alternative explanation of the lateralization of biomechanical 
dysfunction is that compensation from the contralateral limb may be occurring that 
renders it dysfunctional191,192. In this context, targeting TGF-β1 expression in the 
diseased limb may lead to improved myopathy and limb function that reduces need 
for compensation by the contralateral limb. Overall, findings in unilateral PAD 
patients show that what is happening pathologically in the one limb does not affect 
the other, and that pathological changes in the atherosclerotic plaques do not 
significantly contribute to myofibrosis. Rather it is likely the local ischemia-hypoxia 
that the atherosclerotic blockages produce that induces myofibrosis in PAD.  
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CHAPTER IV: REVASCULARIZATION BUT NOT EXERCISE THERAPY 
PREVENTS PROGRESSION OF TGF-β1 ASSOCIATED MYOFIBROSIS IN PAD 
WHILE IMPROVING LIMB FUNCTION, HEMODYNAMICS, AND MYOFIBER 
SIZE 
  
Introduction 
Fibrosis develops in the gastrocnemius of PAD patients with increasing 
disease severity, but it is not known if there are functional consequences. In 
Chapter II, we demonstrated increased collagen density with increasing disease 
stage that appears first around microvessels and then surrounds degenerating 
myofibers. These fibrous changes strongly correlate with expression of 
Transforming Growth Factor-Beta 1 (TGF-β1), a well-established pro-fibrotic 
cytokine. Interestingly, production of TGF-β1 was predominantly localized to 
vascular smooth muscle cells within microvessels of the gastrocnemius and 
inversely correlated with ankle-brachial index, a measurement of blood flow. This 
suggests that atherosclerosis in the large vessels produces ischemia in the smaller 
vessels that upregulates expression of TGF-β1 in smooth muscle cells to stimulate 
pathological fibrosis that is known to be detrimental to end organ function. 
However, due to the cross-sectional design and lack of functional measurements 
in patients of that study, it cannot be determined how the development of fibrosis 
in the skeletal muscle of claudicating PAD patients alters limb function. 
How the development of fibrosis in PAD is affected by the two conventional 
therapies, revascularization and supervised exercise therapy has also not been 
studied. Both treatment modalities produce significant improvements in the 
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walking ability of PAD patients at 6 months122,127,141,193. However, whether these 
improvements are sustained at longer time points is not known. On the other hand, 
in patients with PAD who receive no intervention, a decrease in the walking ability 
has been documented194,195. It is possible that the myopathy of PAD progressively 
worsens in patients who receive no intervention and this worsening is responsible 
for the decrease in their walking ability. Similarly, it is possible that the two standard 
therapies (revascularization and exercise) produce an improvement in the 
myopathy of PAD, which is then reflected in the walking distances at 6 months. 
            A better understanding of how revascularization and supervised exercise 
affects fibrosis development may point to novel therapeutic strategies that can 
sustain, if not enhance, the improved limb function. For example, if the therapies 
do not alter or only modestly decrease expression of TGF-β1 and collagen 
deposition, then fibrosis is an aspect of the myopathy that likely contributes to the 
long-term decline in limb function. Given the strong negative correlation between 
ABI and both TGF-β1 expression and collagen deposition presented in Chapter II, 
revascularization likely will reverse or at least prevent further progression of PAD 
myofibrosis. Additionally, the findings of Chapter III demonstrate that the TGF-β1 
associated myofibrosis is a local response directly related to the extent of 
atherosclerosis of that particular limb. Taken together, it would be expected that 
bypass surgery and endovascular procedures, all of which directly improve blood 
flow, decreases ABI in the revascularized leg of PAD patients136, and thus 
ischemia-reperfusion injury to the muscle, has beneficial effects on PAD myopathy. 
Exercise therapy, on the other hand, does not improve ABI despite demonstrated 
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systemic cardiovascular benefits140. Moreover, the mechanism by which exercise 
improves limb function remains unclear and may be mediated predominantly by 
systemic changes, which the studies of Chapter III showed did not significantly 
contribute to PAD myofibrosis. Based on the differential effects that 
revascularization and exercise have on ABI, benefits may be greater with 
revascularization than exercise for the myofibrosis in PAD patients. If either 
therapy does not significantly reverse myofibrosis, strategies that directly decrease 
TGF-β1 in the muscle are warranted so that adjunct therapies can be developed. 
In this study, we addressed Specific Aim 3 by evaluating the development 
of fibrosis over a period of 6 months in claudicating PAD patients who were treated 
by revascularization or supervised exercise and compared the changes with those 
who were not clinically suitable for either intervention. The relationship between 
TGF-β1, collagen deposition, and assessments of limb function were examined to 
determine the functional consequences of fibrosis development in PAD. We 
hypothesized that revascularization but not supervised exercise therapy improves 
limb function in association with improved TGF-β1 associated fibrosis. 
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Methods 
Characteristics of Human Subjects 
We recruited a total of 72 claudicating PAD patients classified as early stage 
disease, presenting with only intermittent claudication, but no rest pain or tissue 
loss (Fontaine Stage II). The diagnosis for each PAD patients was established on 
the basis of medical history, physical examination, decreased ankle-brachial index 
(ABI < 0.9), and computerized or standard arteriography that revealed stenotic 
and/or occluded arteries supplying the lower limbs. ABI was measured as 
described in Chapter II Methods. The experimental protocol received Institutional 
Review Board approval from the Veterans Affairs Nebraska-Western Iowa and 
University of Nebraska Medical Centers and all patients gave informed consent. 
The patient demographics for CTL, RVS, and EXE patients are presented 
in Table 4.1. There were no differences in age and baseline ankle-brachial index 
among the groups. Smoking history, coronary artery disease, hypertension, 
dyslipidemia, statins medication, myocardial infarction, and diabetes mellitus were 
also were not confounding factors. 
Experimental Timeline and Design 
The 72 patients were divided into the Revascularization (RVS; N=30), 
Exercise (EXE; N=25), and No Intervention (CTL; N=17) groups. All patients 
received a baseline and second biopsy 6 months later. Lower limb functional and 
biomechanical analyses were also performed at baseline and at 6 months. 
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Gastrocnemius samples weighing approximately 250 mg were obtained from the 
anteromedial aspect of the muscle belly, 10 cm distal to the tibial tuberosity, using 
a 6mm Bergstrom needle. The muscle specimen was immediately placed into cold 
methacarn, and after 48 hours, transferred to cold 50% ethanol, and subsequently 
embedded in paraffin. At the start of the 6-month period, patients in the RVS group 
underwent open bypass or endovascular interventions immediately after the 
baseline biopsy. Patients in the EXE group walked on treadmill 3 times per week 
for 45 minutes each, while CTL patients did not receive any interventions. 
Quantitative Assessment of Collagen Density 
Multi-spectral imaging analysis measured the density of collagen as 
previously described in Chapter II Methods. 
 Quantitative Assessment of TGF-β1 Expression 
Quantitative fluorescence microscopy measured the expression of TGF-β1 
expression as previously described in Chapter II Methods.  
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 CTL RVS EXE p-value 
Number of Patients 17 30 25 N/A 
Gender (male/female) 16/1 29/1 25/0 0.983 
Mean Age (years)
 §
 63.2 ± 1.94 62.9 ± 1.38 64.4 ± 1.39 0.733 
Height (m)
 §
 1.75 ± 0.01 1.76 ± 0.01 1.75 ± 0.02 0.965 
Weight (kg)
 §
 89.7 ± 2.61 85.2 ± 3.33 85.6 ± 3.35 0.635 
Body Mass Index
§
 29.3 ± 0.58 27.5 ± 0.98 27.9 ± 1.14 0.481 
Ankle Brachial Index
§
 0.66 ± 0.07 0.56 ± 0.05 0.56 ± 0.04 0.313 
Obesity† (%) 29 20 16 0.570 
Smoking (%) 53 45 68 0.380 
Diabetes Mellitus (%) 29 30 21 0.331 
Dyslipidemia (%) 88 85 89 0.949 
Coronary Artery Disease (%) 24 30 42 0.768 
Myocardial Infarction (%) 6 5 5 0.914 
Hypertension (%) 94 75 84 0.394 
Statins Medication (%) 88 75 95 0.874 
Renal Insufficiency
‡ (%) 12 13 16 0.921 
Table 4.1: Demographics of Claudicants 
 
† Obesity: Body mass index > 30  
‡ Renal Insufficiency: Creatinine clearance < 60 ml/min/1.73m2  
§: Data presented as Mean ± Standard Error  
CTL = No Intervention, RVS = Revascularization, EXE = Supervised Exercise 
 
* p < 0.05 compared to each of the other two groups by post-hoc Bonferroni 
adjusted t-tests  
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Lower Limb Functional Assessments 
Six Minute Walking Distance: Patients walked back and forth along a 100-
meter corridor and the distance that each patient can quickly walk in a period of 
six minutes was measured in meters. The pace was determined by the patient and 
when a patient stopped due to claudication, the measured time continued. Overall, 
this is a measurement of submaximal endurance196,197.  
Peak Walking Time: Patients performed a progressive, graded treadmill 
protocol that consisted of a constant speed of 3.2 km-h-1 at 0° grade incline with 
subsequent 2% increases in speed and incline every 2 minutes. Patient walked 
until maximal claudication pain was induced whereby ambulation could no longer 
continue. Walking time, measured in seconds, was when the patient could no 
longer walk on treadmill198,199.  
 Morphometric Analysis of Myofiber Size 
Greyscale (12-bit) fluorescence images (at 1344 × 1044 resolution) were 
captured with a wide-field, epifluorescence microscope (Leica DMRXA2; North 
Central Instruments, Plymouth, MN) (×10 objective; 0.5128 μm/pixel), a black and 
white CCD camera (Orca ER C4742-95; Hamamatsu Photonics, Bridgewater, NJ), 
and HCImage Hamamatsu software (64-bit version 4.2.5; Hamamatsu Photonics). 
An acquisition matrix was programmed into the HCImage software to cover the 
whole muscle specimen area, acquiring 100–150 microscopic frames per 
specimen yielding images of 134,400 × 104,400 to 201,600 × 156,600 pixels. At 
each location, images were collected in fluorescence channels corresponding to 
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each fluorophore; 1) 4′,6-diamidino-2-phenylindole (nuclei) with an excitation 
maximum at 358 nm and emission maximum at 461 nm, 2) Alexa Fluor 488 
(myosin heavy chains) with an excitation maximum at 495 nm and emission 
maximum at 519 nm, and 3) Alexa Fluor 647 (sarcolemma) with an excitation 
maximum 650 nm and emission maximum at 668 nm. The frames corresponding 
to each fluorophore were montaged in one large image to represent the whole 
muscle specimen. Image segmentation was done with a custom-made Matlab 
algorithm (R2012a; MathWorks Inc, Natick, MA), using thresholding, edge 
detection, regionprops, and a set of heuristics as previously described44,45. Labeled 
sarcolemma acquired at 668 nm provided a binary image that outlined each 
myofiber and was superimposed on the image of myosin heavy chains, allowing 
precise identification of the myofibers for analysis. For each specimen, we 
extracted the measurement of myofiber area. The methods describing how these 
parameters were measured have been described in detail and are illustrated in 
Figure 4.144,45. Briefly, the myofiber area was calculated as the cross-sectional 
area (μ2), from the number of pixels enclosed within a segmented myofiber. 
Biologically, myofiber area can objectively and quantitatively measure pathological 
changes in the muscle, including myofiber degeneration, necrosis, apoptosis, and 
regeneration39,45.          
 Statistical Analysis 
The baseline characteristics among the subject groups were compared 
using general linear models for continuous variables and chi-square tests for 
categorical variables to determine confounders, which if present, were treated as 
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covariates in subsequent analyses. For TGF-β1 expression and collagen 
deposition comparisons at baseline and 6 months, the Wilcoxon Rank-Signed Test 
was used. Correlations were assessed by the Spearman test. The change in each 
of the biological parameters were compared among all three groups using a 
Kruskal-Wallis 1-way ANOVA and difference between pairs of groups were 
analyzed by the Mann-Whitney U test with Bonferroni correction. All statistical 
analyses were performed with SPSS 20 (IBM, Armonk, NY, USA) using a 
confidence level of 95% for the Wilcoxon Rank-Signed, Spearman, and Kruskal-
Wallis tests, and a 98.33% confidence level for the Mann-Whitney U test. 
 
 
 
A                                                                                    C 
Figure 4.1: Morphometric Analysis of Myofiber Size. (A) Sarcolemma labeling 
provided an outline of each myofiber. (B) Myosin labeling served as a confirmation 
that a given sarcolemma outline encompassed a myofiber. (C) The final binary 
segmented image contained the geometry of each myofiber. Note that myofibers 
on the edge of the image were removed, as accurate morphometric parameters 
could not be extracted from only part of the myofibers. 
 
A B C 
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Results 
Development of Myofibrosis in Six Months among PAD Patient Groups: 
QFM imaging revealed increased microvascular TGF-β1 expression in the 
gastrocnemius of CTL patients after six months without interventions, as evident 
by the increased intensity of labeling in the microvessels. A pattern of increased 
TGF-β1 was observed in the EXE patients. In both groups, there are increasing 
numbers of vascular cells that upregulate TGF-β1 after 6 months, forming a more 
uniformly labeled vascular wall. This is consistent with our previous cross-sectional 
study of advanced disease PAD patients (Fontaine Stage IV) compared to 
claudicating PAD patients (Fontaine Stage II). However, TGF-β1 labeling 
remained similar in the RVS group after 6 months (Figure 4.2A). Quantitatively, 
CTL patients had an approximately 2.5-fold greater expression of TGF-β1 after a 
period of 6 months (mean ± s.e.; 3.31 gsu ± 0.49 vs. 1.26 gsu ± 0.17; p < 0.001), 
while EXE patients increased in TGF-β1 about 2-fold (4.46 gsu ± 0.59 vs. 2.35 
gsu ± 0.52, p < 0.001). Patients in the RVS group had TGF-β1 expression levels 
relatively unchanged (2.17 gsu ± 0.33 vs. 2.14 gsu ± 0.42) after 6 months (Figure 
4.2B). Baseline expression of TGF-β1 among the three groups were similar (p = 
0.564), showing that differences among the groups at baseline are not likely a 
confounding variable for the changes observed. 
The difference in TGF-β1 expression before and after six months were 
compared among the groups and differences were detected (χ2 (2) = 24.0, P < 
0.001). Post-hoc tests demonstrated that the change in TGF-β1 in RVS patients 
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was significantly than lower both EXE (U(2) = 620, Z = 4.15, p < 0.001) and CTL 
(U(2) = 71.5, z = -4.06 p < 0.001) patients, with no difference between EXE and 
CTL patients (U(2) = 222, Z = 0.24, p = 0.808; Figure 4.2C).   
Multi-spectral imaging revealed increased collagen density in the 
gastrocnemius of CTL patients after six months without interventions, as evident 
by the increased intensity of labeling in the extracellular matrix between myofibers 
and around microvessels. A similar increase in TGF-β1 was observed in EXE 
patients. In both groups at baseline, there exists a unique pattern of collagen 
deposition, where density of collagen is most intense around microvessels 
compared to collagen that surrounds the myofibers. After six months, collagen 
density continues to increase around microvessels as well as around myofibers. 
Again, this pattern is consistent with our previous cross-sectional study of 
advanced disease PAD patients (Fontaine Stage IV) compared to claudicating 
PAD patients (Fontaine Stage II)201. However, these changes in collagen intensity 
were not present in the RVS group after 6 months (Figure 4.3A). Quantitative 
analysis determined CTL and EXE patients both had an approximately 25% 
increases in TGF-β1 after a period of 6 months (2196 ± 84.2 vs. 1761 ± 56.7 and 
2302 ± 122 vs. 1904 ± 123 respectively; both p < 0.001), while RVS patients had 
relatively unchanged collagen density (1697 ± 77.2 vs. 1662 ± 60.5; p < 0.001) 
after 6 months (Figure 4.3B). Baseline collagen density among the three groups 
were similar (p = 0.351; data not shown), showing that baseline differences are 
not likely a confounding variable for the changes observed.  
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Figure 4.2: Changes in TGF-β1 Expression among Patient Groups. (A) 
Representative gray scale images of gastrocnemius microvessels positive for 
TGF-β1 labeling at baseline and after 6 months of no intervention, 
revascularization, or supervised exercise therapy, were captured with a wide-field 
fluorescence microscope (10x objective). Unlabeled myofibers appear grey 
against a black background. (B) TGF-β1 expression was determined by 
Quantitative Fluorescence Microscopy and defined as the sum of the products of 
area and mean pixel intensity of all positive events per microscopic field, 
normalized to the total area of the specimen in that field. (C) The change in TGF- 
β1 expression compared among the groups. There were significant differences 
between RVS and both CTL and EXE, but not between CTL and EXE patients. 
Significance threshold for all analyses was p < 0.05, except post-hoc tests where 
is p < 0.013. Significance is denoted as * p <0.001 and ** p < .013. 
RVS 
EXE 
C 
122 
 
 
  The change in collagen density were significantly different among the 
groups (χ2 (2) = 20.8, p = 0.001). Post-hoc tests show that the change in collagen 
density in RVS patients was significantly lower than both CTL (U(2) = 61.0, z = -
4.30 p < 0.001) and EXE (U(2) = 572, Z = 3.32, p = 0.001) patients, with no 
difference between EXE and CTL patients (U(2) = 290, Z = -0.46, p = 0.648; 
Figure 4.3C).  Across all times points and patient groups, there was a significant 
positive correlation between TGF-β1 expression and collagen density (r = 0.670; 
p < 0.001), consistent with the previous finding of a robust relationship between 
TGF-β1 and collagen across disease stages (Figure 4.3D). 
 
 
 
 
 
 
 
 
 
A 
B 
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Figure 4.3: Development of TGF-β1 Associated Myofibrosis among Patient 
Groups. (A) Representative gray scale images of gastrocnemius specimens 
stained with Masson Trichrome were captured by multi-spectral, bright-field 
microscopy (20x objective) at baseline and after 6 months of no intervention, 
revascularization, or supervised exercise therapy. Myofibers delineated by 
collagen staining, appear black. Collagen density is represented by the intensity of 
the bright pixels. (B) Collagen density was analyzed by Multi-Spectral Microscopy 
and calculated as area-weighted mean intensity of all collagen events per 
specimen. (C) The change in collagen density compared among the groups by 
post-hoc tests. There were significant differences between RVS and both CTL and 
EXE, but not between CTL and EXE patients. (D) The relationship between TGF-
β1 expression and collagen density at baseline determined by Spearman 
correlation. Significance threshold was p < 0.05, except for post-hoc tests where 
is p < 0.013. Significance is denoted as * p <0.001 and ** p < .013. 
C 
D 
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Limb Function among Patient Groups and Relationship to Myofibrosis: 
 PAD patients in the CTL and EXE groups did not perform differently before 
and after 6 months on the SMWD, and only RVS patients walked further (Figure 
4.4A). The change in SMWD among the groups were significantly different (χ2 (2) 
= 10.6, p = 0.005). Post-hoc tests show that the change in SMWD in RVS patients 
was significantly higher than both CTL (U(2) = 185, Z = 2.46 p = 0.012) and EXE 
(U(2) = 104, Z = -2.92, p = 0.003) patients, with no difference between EXE and 
CTL patients (U(2) = 106, Z = -0.17, p = 0.887; Figure 4.4B).   
Correlation analyses were performed for TGF-β1 expression and collagen 
density against SMWD. At baseline, there was a significant inverse relationship 
between TGF-β1 expression and SMWD (r = -0.245, p = 0.026; Figure 4.4C). 
Unlike TGF-β1, collagen density did not correlate with SMWD at baseline (r = -
0.129; p = 0.298). 
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Figure 4.4: Six-Minute Walking Distance among Patient Groups and 
Relationship to Myofibrosis. (A) The six-minute walking distance, in meters, 
walked by PAD patients who underwent revascularization, exercise therapy, or 
neither intervention. (B) The change in SMWD compared among the groups by 
post-hoc tests. There were significant differences between RVS and both CTL and 
EXE, but not between CTL and EXE patients. (C) Correlation between TGF-β1 
and SMWD at baseline. Significance threshold for all analyses was p < 0.05, 
except post-hoc tests where is p < 0.013. Significance is denoted as * p <0.001 
and ** p < .013. 
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PAD patients in the CTL group did not perform differently before and after 
6 months in their PWT, while both RVS and EXE patients walked longer on the 
graded treadmill test (Figure 4.5A). The change in PWT among the groups after 
six months demonstrated a trend towards significance (χ2 (2) = 5.22, p = 0.073). 
However, post-hoc tests did not demonstrate significant differences between any 
of the individual patient groups (all p > 0.025), although again there was a trend 
towards significantly improved PWT, between both RVS and EXE compared to 
CTL patients (p = 0.028 and p = 0.055 respectively; Figure 4.5B).  
Correlation analyses were performed for TGF-β1 expression and collagen 
density against PWT. At baseline, there was no correlation between TGF-β1 
expression and PWT (r = -0.136, p = 0.283). Again, collagen density did not 
correlate with PWT at baseline (r = -0.132; p = 0.297). 
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Figure 4.5: Peak Walking Time among Patient Groups and Relationship to 
Myofibrosis. (A) Peak walking time, in second, on graded treadmill test by PAD 
patients who underwent revascularization, exercise therapy, or neither. (B) The 
change in PWT compared among the groups by post-hoc tests. There were no 
significant differences among the groups. Significance threshold for all analyses 
was p < 0.05, except post-hoc tests where is p < 0.013. Significance is denoted as 
* p < .013. 
RVS EXE 
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Hemodynamics among Patient Groups and Relationship to Myofibrosis: 
Ankle-Brachial Index (ABI) is the ratio of blood pressure recorded at the 
ankle compared to that of the arm, which reflects blood flow to the lower limbs and 
is considered surrogate measurement of ischemia-hypoxia in PAD. In 6 months, 
the ABI remained relatively stable in both the CTL and EXE patients, but 
significantly increased in RVS patients (Figure 4.6A). Revascularization removes 
atherosclerotic blockages and directly improves blood flow, while exercise therapy 
is thought to improve circulation despite allowing blockages to persist. In these 
patients, ABI was inversely correlated with TGF-β1 expression (r = -0.245, p = 
0.003; Figure 4.6B), consistent with our previous study of claudicating and 
critically ischemic PAD patients23. In patients with lower ABI, or greater ischemia-
hypoxia, there is increasing TGF-β1 expression in microvessels. Collagen density, 
however, did not correlate with ABI (r = -0.075, p = 0.377). 
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Figure 4.6: Hemodynamics among Patient Groups and Relationship to 
Myofibrosis. (A) Ankle Brachial Index in PAD patients before and after 6 months 
of revascularization, exercise therapy, or no intervention. (B) Correlation between 
Ankle Brachial Index and expression of TGF-β1 at baseline. The significance 
threshold for all analyses was p < 0.05. 
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Myofiber Area among Patient Groups and Relationship to Myofibrosis: 
Myofiber cross-sectional area demonstrated a trend towards decreasing 
size in CTL patients, and significantly decreased in EXE patients (Figure 4.7A). 
Patients in the RVS group, however, had increased myofiber area (Figure 4.7A). 
At baseline, expression of TGF-β1 negatively correlated with myofiber area (r = -
0.247, p = 0.007; Figure 4.7B), while collagen density demonstrated a trend 
towards such a relationship (r = -0.160, p = 0.081; Figure 4.7C). In skeletal 
muscle, TGF-β1 is anti-regenerative, so decreasing TGF-β1 may promote 
myofiber regeneration. Less collagen also prevents a physical barrier to myofiber 
regeneration. 
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Figure 4.7: Myofiber Area among Patient Groups. (A) Myofiber cross-sectional 
area in PAD patients before and after 6 months of revascularization, exercise 
therapy, or no intervention. Correlation between (B) TGF-β1 expression and 
myofiber area and (C) collagen density and myofiber area at baseline. The 
significance threshold for all analyses was p < 0.05.  
r = -0.160 
p = 0.081 
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Discussion 
This study examined, for the first time, the effects of two standard therapies 
for PAD patients on the development of myofibrosis over a period of 6 months. 
Overall, there were three important findings. First, in the span of 6 months, there 
was a significant increase in both vascular TGF-β1 expression and collagen 
density in the gastrocnemius of PAD patients who received no interventions. 
Second, revascularization prevented myofibrosis progression in the 
gastrocnemius of PAD patients while improving their walking times and distances. 
In these patients, both the ABI and myofiber cross-sectional area were increased, 
indicating potential mechanisms by which limb function improved. Finally, 
supervised exercise therapy improved only peak walking time, and was associated 
with progression of myofibrosis in the gastrocnemius, similar to PAD patients who 
received no interventions.   
This study is also the first to evaluate the association of TGF-β1 expression 
and collagen density to limb function in PAD patients. At baseline, there was a 
significant inverse correlation between TGF-β1 and SMWD, but no correlation 
between collagen density and SMWD. There was not a significant relationship 
between TGF-β1 or collagen and PWT. Overall these data suggest first, that TGF-
β1 expression is more closely related to limb function than collagen density. TGF-
β1 expression may be a rapid response to hypoxia, which would have direct 
negative effects on muscle and limb function. For example, hypoxia is expected to 
compromise energy production in the myofibers. On the other hand, collagen 
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deposition, which is mediated by TGF-β1, may be viewed as a somewhat delayed 
response to hypoxia. Alternatively, TGF-β1 may have a direct negative effect on 
myofiber regeneration and contribute to the reduced limb function in these patients. 
Second, the data suggest that TGF-β1 expression better reflects SWMD than PWT 
performance. Since PAD patients are often tested on treadmill, inherent training 
effects may mask TGF-β1 associated detrimental effects on PWT. Although the 
relationship between TGF-β1 expression and SMWD was significant, it is not 
robust, suggesting one or both of two possibilities. First, the suppressive effects of 
TGF-β1 on muscle regeneration account for only a small fraction of limb 
dysfunction. Second, if both TGF-β1 and limb dysfunction, e.g., caused by a deficit 
in energy metabolism, are driven by hypoxia, the strength of their responses to 
hypoxia may be significantly different.    
Without interventions, claudicating PAD patients experience a significant 
increase in TGF-β1 expression and collagen density in their gastrocnemius in just 
6 months, although this was not associated with a significant decline in limb 
function. The lack of limb function decline in PAD patients without intervention may 
reflect the significant but not robust relationship between TGF-β1 expression and 
limb function. This is in line with PAD being a chronic disease, where it likely takes 
multiple myopathic changes over time to reach a threshold of damage that will 
produce limb dysfunction. In addition to promoting fibrosis, the increased TGF-β1 
expression may have a direct suppressive effect on muscle regeneration or may 
be functioning as a biomarker associated with other pathogenic events that 
decrease limb function. This is supported by our finding that in 6 months, patients 
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who did not receive either revascularization or exercise therapy present with a 
trend towards decreasing myofiber cross-sectional area and myofiber 
degeneration. Furthermore, decreased myofiber area correlated with increased 
expression of TGF-β1. TGF-β1 is known to stimulate myoblasts to differentiate into 
myofibroblasts rather than new myofibers70,71,158 and may limit regeneration of the 
chronically ischemic skeletal muscle. Accumulation of fibrotic tissue offers an 
unfavorable environment for myogenesis and decreases the efficiency of force 
transmission from the sarcomere to the extracellular matrix70,71,158. Indeed, there 
was a trend towards an inverse relationship between myofiber area and collagen 
density. Thus, these findings demonstrate the importance of an intervention that 
may be able to target TGF-β1 production by SMCs in PAD muscle and potentially 
improve limb function.  
Claudicating PAD patients treated with revascularization demonstrated an 
arrest in the progression of myofibrosis, which was associated with improved limb 
function. Revascularization prevented an increase in vascular TGF-β1 expression 
and collagen density that was detected in the gastrocnemius of PAD patients who 
received no interventions. Preventing increased TGF-β1 expression may 
contribute to improvements in SMWD by a mechanism that spares myofiber 
regeneration. RVS patients were the only group of patients that had increased 
myofiber area, which is indicative of regeneration. The robust inverse relationship 
of TGF-β1 expression to myofiber area further supports regeneration as a 
mechanism. However, future studies should evaluate for markers of regeneration, 
such as MyoD, to verify200. Both the increased limb function and myofiber cross 
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sectional area may be due to improved hemodynamics and tissue oxygenation, 
since RVS patients were the only group of patients that had increased ABI. At 
baseline, ABI strongly correlated with TGF-β1 expression, suggesting that 
increased blood flow and thus, reduced ischemia-reperfusion injury contributes to 
preventing the progression of myofibrosis and improving limb function with 
revascularization.  
A 6-month supervised exercise regimen improved the walking ability of PAD 
patients, but did not alter the development of myofibrosis that was observed in 
untreated PAD patients. Patients who participated in supervised exercise walked 
longer on treadmill, as reflected by greater PWT, but exhibited no change in their 
SMWD. The increased PWT has been widely reported in the literature140, but only 
two studies have examined changes in SMWD and both demonstrated increases 
with exercise141,142. An explanation may be that our study is underpowered 
compared to those two studies which had at least twice as many PAD patients. 
The estimated effect size for SMWD (0.70) is relatively smaller than that of PWT 
(1.01) and would require more patients to demonstrate a statistical significance132, 
which is consistent with the findings of this study. An alternative explanation is that 
in our study, patients were recruited when they were referred to vascular surgery 
as opposed to the other two studies that recruited patients from various social 
outlets, such as advertising. PAD patients in our study may have more advanced 
disease despite falling into the same Fontaine Stage II classification and 
improvements in submaximal endurance may be minimized. Such an effect may 
not similarly apply to PWT since the graded treadmill provides a very similar 
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environment to the supervised exercise therapy they receive. Thus, a part of the 
improvement may be due to a training effect, in which the leg muscles of these 
PAD patients have been trained to perform treadmill exercise and develop 
tolerance that allows them to improve their performance further. SMWD, however, 
is more reflective of how patients would exercise in their daily lives. Finally, 
exercise is thought to improve conditioning of the body for maximal exertion such 
as that on the graded treadmill test, and thus, is where the benefits may be best 
observed rather than endurance with SMWD.     
Both TGF-β1 expression and collagen density increased in patients who 
participated in exercise therapy and their relative increases were similar to those 
of the control group. This suggests that exercise does not change the natural 
history of myofibrosis in the skeletal muscle of PAD patients. With exercise, there 
was no change in ABI and there was a decrease in myofiber area. These findings 
demonstrate that the benefits of exercise may be independent of blood flow, TGF-
β1 associated myofibrosis, and myofiber regeneration. The mechanism may be 
through systemic cardiovascular benefits, increased perfusion of blood at the 
microvascular level, or a different aspect of PAD myopathy such as increasing 
energy metabolism in the muscle201,202. However, improvements have been 
attributed to training effects that improve the tolerance of PAD patients to 
claudication symptoms while performing the graded treadmill test, and 
psychologically patients feel they should improve performance having been trained 
on the treadmill128,129. Exercise may actually be physically damaging to the skeletal 
muscle by increasing the bouts of ischemia-reperfusion, which may 
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counterbalance potentially positive effects on myofibrosis. Overall, the functional 
improvements with exercise therapy appear unrelated to myofibrosis. 
One reason why revascularization and not exercise therapy prevents 
myofibrosis progression could be that revascularization directly targets blood flow 
and thus ischemia-reperfusion injury, while exercise at best, indirectly targets 
ischemia-reperfusion. Among the study groups, only patients receiving 
revascularization improved their ABI. Exercise therapy, on the other, does not 
increase ABI in PAD patients of this study, which is not unexpected given the 
blockages are left intact138. ABI, in turn, predicts microvascular TGF-β1 
expression, such that as ABI decreases, which reflects increasing ischemia and 
hypoxia, TGF-β1 levels increase. Revascularization restores blood flow to the 
microvessels, which should in theory prevent further production of TGF-β1 by 
vascular smooth muscle cells. Yet, TGF-β1 levels are not reduced as would be 
expected by the inverse relationship between ABI and TGF-β1 expression. This 
recapitulates the insidiousness of PAD myopathy and points to the major problem 
with revascularization as a conventional therapy. Previous biomechanical, blood 
flow, and oxygen kinetic studies show that even before the skeletal muscle of PAD 
patients becomes ischemic, that they already present with gait dysfunction22-26. It 
seems that once ischemia-reperfusion has induced increased vascular TGF-β1 
expression, restoration of blood flow does not significantly reduce TGF-β1 
expression and reverse myofibrosis. Although as a whole group, RVS patients had 
unchanged TGF-β1 expression, many patients did have decreased TGF-β1 
expression and correspondingly less dense collagen. This demonstrates that at 
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this early stage of PAD progression, myofibrosis may be reversible in some 
patients. Further studies aimed at understanding the characteristics of these 
“responders” and the circumstances under which revascularization may reverse 
fibrosis should be rigorously pursued. 
Another benefit of preventing the increased TGF-β1 levels detected in 
untreated patients is that the compensatory regeneration response is allowed to 
proceed more effectively. Patients who underwent revascularization were the only 
ones who had increased myofiber area, which in the context of PAD, points to 
myofiber regeneration occurring. Although these new myofibers have better 
contractile abilities and will improve overall limb function, they are vulnerable to the 
pro-fibrotic environment that persists and may become atrophic and degenerate in 
the future. PAD patients who claudicate, do not maintain their limb function and 
succumb to sedentary lifestyles, further aggravating other cardiovascular co-
morbidities. With myofibrosis still a hindrance and the possibility of these additional 
insults to regenerating myofibers, the likelihood of aging PAD patients preserving 
their limb function and quality of life is low. Thus, given the anti-regenerative 
properties of TGF-β1, adjunct therapies that decrease its expression may preserve 
healthy myofibers that contribute to improved limb function in PAD patients. 
In conclusion, this study reinforces TGF-β1 associated myofibrosis as an 
important marker of PAD myopathy and disease progression, and reveals how the 
two conventional therapies, revascularization and supervise therapy, affect 
development of this pathology. Fibrosis has been linked to end organ dysfunction 
140 
 
and when it occurs in the skeletal muscle, is highly disruptive69. Around myofibers 
it restricts normal contractile properties and in microvessels, interferes with oxygen 
and nutrient delivery, all of which predisposes the muscle to dysfunction and 
degeneration70,71,158. Although this study demonstrated only a weak, although 
significant, relationship between TGF-β1 and limb function, the myofibrosis that 
TGF-β1 induces can leave the skeletal muscle vulnerable to development of 
additional myopathies, which once progressing together, decreases limb function. 
We further demonstrated that neither of the two conventional therapies can reverse 
myofibrosis. However, revascularization but not supervised exercise therapy 
prevented progression of myofibrosis in PAD gastrocnemius. This suggests that, 
clinically, long-term benefits to the lower limb of PAD patients are better with 
revascularization than exercise and that preventing myofibrosis progression is a 
contributing mechanism. Thus, adjunct therapies that can reverse or further inhibit 
development of myofibrosis may help maintain or improve the limb function and 
quality of life of PAD patients. 
 
  
 
 
 
141 
 
CHAPTER V: CONCLUSION 
  
Model of PAD Myofibrosis 
            The work presented in this dissertation provides insight into the 
development of myofibrosis in PAD patients, its functional consequence, and how 
current standard therapies affect this myofibrosis. The overarching hypothesis was 
that decreased hemodynamics drives a local TGF-β1 associated increase in 
collagen deposition within the gastrocnemius of PAD patients that increases with 
disease severity, and that this myofibrosis is reversed by revascularization but not 
exercise therapy in association with improved limb function. Three specific aims 
were developed to test this hypothesis. The first aim was to investigate the 
relationships among limb hemodynamics, and both TGF-β1 expression and 
collagen deposition in the gastrocnemius of PAD patients at advancing disease 
stages to establish the presence and potential etiology of myofibrosis. The second 
aim was to determine whether TGF-β1 associated myofibrosis in the 
gastrocnemius of PAD patients is a localized response in the ischemic muscle or 
response to systemic events. The third aim was to determine changes in 
myofibrosis in relation to limb function, hemodynamics, and myofibers size, in PAD 
patients who have undergone revascularization or exercise therapy. 
 Studies that addressed the first specific aim established a TGF-β1 
associated myofibrosis by the robust correlation between TGF-β1 and collagen 
density that increases in the gastrocnemius with the severity of disease in PAD 
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patients (Fontaine Stage II to IV). The increased production of TGF-β1 was 
determined to be predominantly by vascular SMC, rather than immune cells or 
endothelia, suggesting a vascular etiology and downstream consequence of 
atherosclerotic blockages. The relationship between ABI and SMC-derived TGF-
β1 is further suggestive that altered hemodynamics and the resulting hypoxia, 
caused by the atherosclerotic blockages in the named vessels, may induce 
expression of TGF-β1 by SMC at the microvascular level. Activation of SMC from 
a contractile to a synthetic phenotype capable of promoting fibrosis was evidenced 
by its proliferative state and cobblestone, rather than spindle shaped morphology. 
Consistent with the well-known mechanism of fibrosis, whereby TGF-β1 activates 
myofibroblasts to secrete excessive extracellular matrix, TGF-β1 was found 
closely associated with fibroblastic cells around the microvessels, along with 
increased collagen density and area in the adjacent myofiber tissue. Ischemia and 
hypoxia experienced by SMC of microvessels may be driving the increased 
production of TGF-β1 by SMC, which activates fibroblastic cells. These activated 
fibroblasts have the known ability to migrate to areas around the myofibers and 
deposit extracellular matrix. Indeed, we localized fibroblasts to collagenous areas 
around myofibers. Overall the vascular etiology of TGF-β1 associated myofibrosis 
is in line with PAD disease being a vascular disease.  
            Studies that addressed the second specific aim established that the TGF-
β1 associated myofibrosis is a localized response that develops with early disease 
(Fontaine Stage II) in the presence of atherosclerosis in the diseased limb, rather 
than a response to systemic changes associated with atherosclerosis. Although 
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the increased production of TGF-β1 by microvascular SMC could be a response 
to local ischemia and hypoxia of the diseased leg, systemic contributions cannot 
be ruled out, such as pro-fibrotic factors in circulation that increase with disease 
severity that may also be inducing the production of TGF-β1 by SMC. Since the 
majority of PAD patients have bilateral disease, it is difficult to know if systemic 
contributions exist, but this can be determined by comparing the limbs of PAD 
patients with unilateral disease. The greater expression of TGF-β1 and collagen 
density in the diseased compared to contralateral leg and the lack of correlation 
between the limbs in both measures, indicated that systemic effects were minimal. 
Furthermore, a TGF-β1 associated myofibrosis did not exist in the contralateral 
compared to the diseased leg, further suggesting that atherosclerosis and its 
hemodynamic consequences on the microvessels is needed to produce TGF-β1 
associated myofibrosis. These findings demonstrate that TGF-β1 associated 
myofibrosis is primarily a localized response in the ischemic muscle.   
            Finally, studies that addressed the third specific aim characterized the 
progressive development of this TGF-β1 associated myofibrosis over a 6 month 
period in early stage PAD patients, and determined its response to the standard 
therapies of revascularization and supervised exercise and associations with 
changes in limb function. Our previous studies comparing age-matched controls 
with early and advanced PAD disease was cross-sectional and did not allow us to 
determine the progressive development of TGF-β1 associated myofibrosis in PAD 
patients. This prospective study found that the gastrocnemius of PAD patients who 
had no interventions during the 6 month period demonstrated a significant increase 
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in TGF-β1 associated myofibrosis in their gastrocnemius, but this did not produce 
changes in the limb function measurements of PWT or SMWD. With supervised 
exercise, there was still a significant increase in TGF-β1 associated myofibrosis, 
despite improved PWT, although there was no change in SMWD performance. 
PAD patients who underwent revascularization did not exhibit an increase in TGF-
β1 associated myofibrosis, and performed significantly better on both PWT and 
SMWD. This may be attributed to the improved hemodynamics, reflected by 
significant increase in ABI, measured in revascularization patients that was not 
found in patients who had no interventions or participated in exercise therapy. 
Alternatively, it may be attributable to increased myofiber regeneration, since only 
in the revascularization group was there an increase in the myofiber size compared 
to the no intervention and exercise groups. 
            Taken together, the findings of these three specific aims tested the 
overarching hypothesis. Hemodynamics is tightly linked to the increased TGF-β1 
expression by SMC, which is strongly correlated with collagen deposition that 
increased with advancing Fontaine disease stage in PAD patients. These 
myofibrotic changes are indeed a local response that is associated with the 
decreased hemodynamics of the affected limb caused by atherosclerosis. Finally, 
as hypothesized, supervised exercise therapy did not reverse myofibrosis, but 
neither did revascularization, although it did halt the progression of myofibrosis in 
6 months. Preventing myofibrosis progression was accompanied by improvements 
in both the ability of PAD patients to walk further and longer. Interestingly, however, 
TGF-β1 but not collagen density was associated with these improvements, 
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particularly walking distance. Perhaps TGF-β1 is an early response directly 
associated with ischemia-reperfusion and the consequently hypoxic environment 
that is detrimental to the muscle, while deposition of collagen is a later response 
induced by TGF-β1 that requires more time to impact limb function in Fontaine 
Stage II PAD patients. Alternatively, TGF-β1 may impact function by additional 
biological roles in the skeletal muscle of PAD patients besides fibrosis, such as 
inhibiting regeneration. Overall, these studies show that the best that standard 
therapies can do for TGF-β1 associated fibrosis is to halt progression and thus it 
is imperative to understand the mechanism driving the increased TGF-β1 
expression by vascular SMC to develop therapeutic strategies that directly target 
the development of myofibrosis.  
In summary, this dissertation adds knowledge to an aspect of myopathy that 
has not been well studied and links it to the known pathophysiology of PAD. The 
lower limbs of PAD patients experience cycles of ischemia-reperfusion that impairs 
limb function. However, how altered hemodynamics and oxygenation levels may 
affect the skeletal muscle of PAD patients to produce a myopathy that contribute 
to the decreased limb function is unknown. The finding that increased TGF-β1 
expression by SMC of microvessels is inversely correlated with ABI suggests that 
the changes produced by atherosclerosis of the named vessels can adversely 
activate pro-fibrotic changes in the smaller vessels. Increased TGF-β1 is strongly 
associated with collagen deposition with significant progression in 6 months during 
early stages of disease, and this relationship holds over years to more advanced 
stages. Furthermore, the development of this myofibrosis is a local response rather 
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than caused by systemic effects. Progression of myofibrosis was halted by 
revascularization, but supervised exercise did not affect this change, as it did not 
improve or worsen the progression. This model of PAD myofibrosis is illustrated in  
 
Figure 5.1. 
 
 
 
 
 
 
 
 
 
Figure 5.1: Model of Myofibrosis in PAD. 
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Future Directions 
 In addition to better understanding the development of another component 
of the myopathy afflicting PAD patients, the work presented in this dissertation also 
points to future potential mechanisms to be studied. Central to these studies 
should be understanding how TGF-β1 expression by SMC of microvessels is 
increased, given it is an early marker of the disease that progresses with stage, 
significantly correlates with limb function performance, and is not decreased by 
revascularization or supervised exercise. One potential inducer could be cycles of 
ischemia-reperfusion, which can be modeled by alternating hypoxia and normoxia 
conditions. Such hypoxia-normoxia may directly shift the phenotype of SMC from 
contractile to the synthetic form that is characterized by increased expression of 
TGF-β1. In future in vitro studies, we will examine if alternating cycles of hypoxia-
normoxia can induce the expression of TGF-β1 in human internal thoracic artery 
smooth muscle cells (HITASMC) and shift the phenotype from a contractile to a 
synthetic one.  
Alternatively, cycles of hypoxia-normoxia may induce endothelia to secrete 
pro-fibrotic factors that activate SMC to produce TGF-β1. This is supported by 
preliminary observations in our laboratory of the close physical association of SMC 
and endothelia in the subendothelial region, suggestive of pathological signaling 
interactions. Two potential candidate pro-fibrotic markers that endothelia may 
release are Platelet Derived Growth Factor (PDGF)-BB and Connective Tissue 
Growth Factor (CTGF)70,71. In future studies, we will first label for PDGF-BB and 
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CTGF in the gastrocnemius of Fontaine Stage II and IV PAD patients along with 
age matched controls to determine if there is increased expression of either factor 
in endothelia, and if these changes correlate with the expression of TGF-β1 
expression in the same biopsy sample. If results are promising of their 
involvement, then in vitro studies will be conducted to determine if cycles of 
hypoxia-normoxia induce PDGF-BB and CTGF expression in human internal 
thoracic artery endothelial cells (HITAEC), if transfer of supernatant to HITASMC 
will induce increased TGF-β1 expression, and if addition of a neutralizing antibody 
to each factor will reverse the findings. Overall, these studies on the mechanisms 
by which TGF-β1 is increased will point to novel therapeutic targets. If any of these 
mechanisms prove to be important, then these cells from the microvessels of PAD 
patient gastrocnemius can be isolated and similar experiments performed.  
Ultimately, the goal will be to understand how atherosclerotic blockages in 
the named vessels leads to the pathophysiological changes not just in the 
microvessels of the gastrocnemius but of vessels of various sizes in between. It is 
still unknown how the increase in TGF-β1 in SMC that occurs focally at the 
atherosclerotic sites spreads downstream. Additionally, the context with which 
TGF-β1 is increased and the consequences appear to be different as well, where 
SMC within a plaque proliferate and migrate into the intimal layer to promote 
formation of a fibrous cap, whereas in the microvessels proliferate within the media 
and promote fibrotic thickening of that layer but not many are seen promoting 
plaque formation or even significant thickening of the intimal wall. Beyond the 
media layer of microvessels, TGF-β1 activates fibroblastic cells to promote 
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myofibrosis, and it has been suggested that by an autocrine mechanism may 
stimulate SMC nearby along the vessel wall to increase TGF-β1 expression. 
Perhaps this is a similar mechanism that occurs around the vessel segment with 
atherosclerosis. However, ischemia-hypoxia may not play a critical role distal to 
the atherosclerosis compared to microvessels. Other potential mechanisms may 
include disturbed flow that can activate sensors in endothelia that is known to 
promote vascular remodeling, which may include induction of TGF-β1 expression 
by SMC. And for vessels further downstream, perhaps both disturbed flow and 
ischemia-hypoxia are important. Finally, circulatory factors originating from the 
atherosclerotic plaque may flow through the vasculature distal to the blockage and 
contribute to development of TGF-β1 associated myofibrosis of that particular leg. 
Understanding how pathological changes are propagated down the vasculature 
distal to a blockage that results in elevated TGF-β1 expression from SMC in the 
end organ skeletal muscle is necessary to interdict myofibrosis at its root cause.   
This is not to say that understanding the additional effects of TGF-β1 in the 
skeletal muscle, such as myofiber regeneration, are not important. TGF-β1 has 
known anti-regenerative effects in skeletal muscle and its increased expression by 
the microvessels may reflect a compensatory mechanism early on to increase the 
force of contraction for adequate delivery of blood to the lower extremities. 
However, with progression of the disease, may serve as a means to wall off flow 
and nutrient delivery, as well as gas and waste exchange, to skeletal muscle that 
is beyond repair. Such a theory may also be applicable to the skeletal muscle itself, 
where activation of increased activation fibroblasts by TGF-β1 is to directly 
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stimulate the repair process, and thus bypass the immune mediated mechanism 
that requires resolution of inflammatory responses that may release cytotoxic 
ROS. If adequate flow is not restored in a timely manner and myofibers are beyond 
repair, the excessive amounts of TGF-β1 then triggers a fibrotic response that fills 
in the space left behind by the dying skeletal muscle for stabilization of the lower 
limb. It may be that at some point, even if adequate flow is restored this sequelae 
will still continue, despite the limb being able to be salvaged and that is where 
interventions that directly reduce TGF-β1 may help. If this theory is true, how the 
vasculature and skeletal muscle coordinates such a response will need to be 
explored, since this may affect our understanding of the development of fibrosis 
and end organ damage in other parts of the body. During the development of PAD, 
the increasing TGF-β1 may act as a molecular switch to turn off regenerative 
processes that would waste valuable resources and divert myoblasts to accelerate 
the fibrotic response that stabilizes the leg with scar tissue.    
Beyond the mechanistic aspects, uncovering TGF-β1 as a novel marker of 
disease progression that develops early in PAD pathophysiology has important 
prognostic value. One of the most important findings from this dissertation is that 
the early increase in TGF-β1 is strongly linked to hemodynamic compromise. Our 
laboratory and others have been reported increased oxidative damage in the 
skeletal muscle of PAD patients, and we have observed increased carbonyl and 
4-hydroxynonenal damage in cells of the microvessels in the gastrocnemius of 
Fontaine Stage II PAD patients. Along with markers of mitochondrial dysfunction 
and myofiber morphometrics, carbonyl and 4-hydroxynonenal oxidative damage 
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and TGF-β1 can form a biomarker panel that may be able to predict the decline of 
limb function of patients with no interventions and outcomes of revascularization 
and supervised exercise therapies. It would also be interesting to determine if 
increasing TGF-β1 levels predict the other biomarkers and whether any predicts 
the others, which would provide clues as to the earliest trigger of PAD myopathy. 
It would also test the theory above that TGF-β1 is first a compensatory mechanism 
to supply more blood to the limbs but at some point becomes a molecular switch 
that promotes pathological fibrosis. Finally, staging of PAD patients, such as with 
the Fontaine stages, remain a crude designation of disease development. Fontaine 
stages are solely based on overt symptoms, and often the decision to 
revascularize or start supervised exercise therapy does not take into account the 
myopathy present in the legs of PAD patients. Future development of guidelines 
for prognosis and for optimal use of current therapeutics taking into account 
myopathy will be beneficial to the management of PAD patients.  
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